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Zusammenfassung 
Staphylococcus aureus ist einer der weltweit häufigsten Erreger von nosokomialen und auch Spital 
unabhängigen Infektionen. S. aureus hat die Fähigkeit, Resistenzen gegen nahezu alle klinisch 
verwendeten Antibiotika zu entwickeln, wodurch die Behandlungsmöglichkeiten und der 
Behandlungserfolg einschränkt werden. Das Resistenzniveau und die intrinsische Toleranz von 
S. aureus gegen Antibiotika wird durch verschiede genomische Faktoren beeinflusst.  
 
Einer dieser Faktoren ist das Zweikomponentensystem VraSR, welches die Stressantwort auf 
zellwand-aktive Antibiotika kontrolliert. Das Zweikomponentensystem reguliert Zellwand-
Biosyntheseenzyme hoch und Autolysine runter, was einen intrinsischen Schutz von S. aureus gegen 
Zellwand-Antibiotika zur Folge hat. Im ersten Teil dieses Projektes wurde die Induktionskinetik vom 
VraSR-abhängigen Zellwand-Stress Stimulon von zehn Antibiotika mit Hilfe eines Luziferase-
Reporterkonstrukts bestimmt. Hierbei wurde eine deutliche Korrelation zwischen der 
Induktionskapazität eines Antibiotikums und seinem bakteriziden Effekt aufgezeigt. Die 
Konzentrationsabhängigkeit der Induktion und die Lag-Phase waren für verschiedene Antibiotika 
variabel. Die Relevanz von VraSR für die Resistenz und die intrinsische Toleranz von verschiedenen 
Zellwand-Antibiotika wurde mit Hilfe einer VraR-Mutante validiert und liess eine speziell wichtige 
Rolle der von VraSR kontrollierten Stressantwort für den Schutz von S. aureus gegen Bacitracin, 
Flavomycin und Teicoplain erkennen. 
 
Ein weiterer Faktor mit Einfluss auf die Methicillin-Resistenz von S. aureus ist die sogenannte LytR-
CpsA-Psr (LCP) Proteinfamilie. In Bacillus subtilis wurde entdeckt, dass LCP Proteine die Ligation 
von Wandteichonsäuren an das Zellwand-Pepidogylcan katalysieren, den für lange Zeit unbekannten 
Schritt in der Biosynthese vom wichtigen Zellwandbestandteil Wandteichonsäuren. In diesem 
Projektteil konnte dieselbe Funktion indirekt für die drei LCP Proteine von S. aureus bestätigt werden 
mittels einer nahezu nicht mehr detektierbaren Menge von Wandteichonsäuren in der LCP 
Dreifachmutante. Der Zusammenhang von LCP Proteinen und der Biosynthese von 
Wandteichonsäuren wurde weiter erhärtet durch die partielle Komplementierung des 
Wachstumsdefektes der LCP Dreifachmutante durch Hemmung des ersten Biosyntheseschrittes von 
Wandteichonsäuren (TarO). Diese Hemmung von TarO verhindert wahrscheinlich die Akkumulierung 
von toxischen Zwischenprodukten und die Blockade des Lipidträgers, wodurch die nachteiligen 
Effekte der LCP Deletion teilweise aufgehoben werden. Weil die drei LCP Proteine zum VraSR-
Regulon gehören, wurde ihre Verbindung zum Zellwand-Stress Stimulon untersucht. Die Deletion von 
LCP Genen führt zu einer starken Induktion der VraSR abhängigen Zellwand-Stressantwort; 
vergleichbar mit der bisher bekannten Induktion infolge der Limitierung von essentiellen Zellwand- 
oder Wandteichonsäuren-Biosyntheseenzymen und impliziert daher ebenfalls einen Zusammenhang 
von LCP Proteinen und der Biosynthese der Zellhülle. 
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Im dritten Teilprojekt wurde ein genetischer Faktor entdeckt, der die Methicillin-Resistenz und die 
Fitness von Methicillin-resistenten S. aureus (MRSA) beeinflusst. Die Sequenzierung des gesamten 
Genoms von zwei theoretisch genetisch identischen MRSA mit Unterschieden in der Wachstumsrate 
und der Methicillin-Resistenz zeigte nur einen Einzelnukleotid-Polymorphismus (SNP) im 
Diadenlyate Zyklase Gen dacA auf. DacA synthetisiert den kürzlich entdeckten sekundären Botenstoff 
c-di-AMP, ein Signalmolekül das zuvor schon mit der Zellwand-Homöostase in Verbindung gebracht 
wurde. Es konnte bestätigt werden, dass reduzierte zelluläre Mengen von c-di-AMP, infolge der 
Mutation in dacA, mit einem erniedrigten Beta-Lactam Resistenzniveau und mit einer erhöhten 
Wachstumsrate korrelieren.  
 
Das vierte Teilprojekt untersuchte den Effekt einer Standardbehandlung mit Minocyclin, Amoxicillin 
oder Placebo auf die S. aureus-Population von gesunden Freiwilligen. Die S. aureus-Isolate wurden 
durch einen Partner des Intereuropäischen 7. Rahmenprogramm Projekts ‚ANTIRESDEV‘ gesammelt, 
der die klinische Studie durchführte. Die S. aureus-Isolate wurden im Detail analysiert in Bezug auf 
Antibiotikaresistenz-Profile, Fitness, MLST-, PFGE- and spa-Typen. Die Kombination der 
Fitnessdaten und des Resistoms zeigte keine offensichtliche Korrelation zwischen der Fitness und der 
Präsenz oder Abwesenheit von Resistenzgenen oder des Resistenzniveaus. Die Freiwilligen waren im 
Allgemeinen nur von einem spezifischen S. aureus-Stamm besiedelt. Interessante Isolate von einem 
Freiwilligen mit drei verschiedenen Stämmen wurden noch detaillierter analysiert. Die Resultate der 
Studie suggerieren, dass sich aufgrund einer Standardbehandlung mit Amoxicillin oder Minocyclin 
keine Resistenzen oder Anreicherungen von Resistenzgenen in den kommensalen S. aureus 
entwickeln. 
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Summary 
Staphylococcus aureus is one of the major causes of both nosocomial and community acquired 
infections worldwide. S. aureus is able to acquire resistance to virtually all antibiotics prescribed 
limiting treatment options and impairing treatment outcomes. Resistance levels or intrinsic tolerance 
to antibiotics is influenced by various genetic factors of S. aureus.  
 
One of these factors is the two-component system VraSR that controls a stress response to cell wall-
active antibiotics. The VraSR two-component system up-regulates cell wall biosynthesis enzymes and 
down-regulates autolysins resulting in an intrinsic protection of S. aureus against cell wall antibiotics. 
In a first part of this project induction kinetics of the VraSR-dependent cell wall stress stimulon in 
response to ten antibiotics were determined using a luciferase reporter construct. A clear connection 
between the induction capacity of an antibiotic and its bactericidal effect was shown. The 
concentration dependency of induction and lag phases were found to be variable for different 
antibiotics. The importance of VraSR for resistance or intrinsic tolerance to different cell wall active 
antibiotics was validated using a VraR mutant strain revealing that the VraSR controlled stress 
response is especially important in protection of S. aureus against bacitracin, flavomycin and 
teicoplanin. 
 
Another factor influencing methicillin resistance of S. aureus is the so-called LytR-CpsA-Psr (LCP) 
protein family. LCP proteins were suggested to catalyse the long missing step of ligation of the 
important cell wall component wall teichoic acids to the cell wall peptidoglycan in Bacillus subtilis. 
This was indirectly confirmed for the three S. aureus LCP proteins by showing that the amount of wall 
teichoic acids was almost abolished in a S. aureus triple LCP mutant in this part of the project. The 
connection of LCP proteins to biosynthesis of wall teichoic acids was also substantiated by partial 
complementation of the growth defects of the LCP triple mutant by inhibiting the first step of WTA 
synthesis (TarO). The inhibition of TarO probably limits accumulation of toxic intermediates or 
blockage of the lipid carrier, partially rescuing the detrimental effect of LCP deletion. Since the three 
LCP genes belong to the VraSR regulon, the connection to the cell wall stress stimulon was analysed. 
Deletion of LCP genes highly induced the VraSR system similar to the depletion of essential cell wall 
or wall teichoic acid biosynthesis enzymes observed previously, providing thereby another 
confirmation for a connection of LCP proteins to cell envelope biosynthesis. 
 
The third subproject identified a genetic factor that influences both methicillin resistance and fitness of 
MRSA. Whole genome sequencing of two theoretically genetically identical MRSA with different 
fitness and resistance characteristics revealed only one single nucleotide polymorphism (SNP) in the 
diadenlyate cyclase gene dacA. DacA synthesises the recently discovered second messenger c-di-AMP, 
a signalling molecule that was before connected to cell wall homeostasis. It was confirmed that the 
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reduced cellular level of c-di-AMP caused by the dacA mutation correlates with a decrease in beta-
lactam resistance levels and increases in the growth rate. 
  
The fourth sub-project analysed the effect of a standard therapy with minocycline, amoxicillin or 
placebo on the S. aureus population of healthy volunteers. The S. aureus isolates were collected by a 
partner of the Intraeuropean 7th framework project ‘ANTIRESDEV’ who performed the clinical study. 
The S. aureus isolates were analysed in detail with respect to their antibiotic resistance profile, fitness, 
MLST, PFGE and spa types. The combination of the fitness data and the resistome showed no 
apparent correlation between the fitness and the presence or absence of resistance genes, or the 
resistance levels. Volunteers carried generally only one specific S. aureus strain. Interesting isolates 
from one volunteer who carried three different strains were analysed in more detail. The results of the 
study suggest that there is no resistance development or accumulation of resistance in commensal 
S. aureus strains upon a standard treatment with amoxicillin or minocycline. 
1 Introduction 
 
6
1 Introduction 
1. 1  Staphylococcus aureus – profile of a successful pathogen 
1. 1. 1   Taxonomy, morphology and general biology 
Staphylococcus aureus is a Gram-positive non-spore forming and non-motile bacterium that belongs 
to the family of Gram-positive cocci, Staphlyococcaceae, in the order of Bacillales in the phylum 
Firmicutes. S. aureus is a spherical bacterium that forms grape like cell aggregates and often 
yellow/golden colonies (Figure 1), three characteristics that led to its name. Staphyl originates from 
the Greek word ‘staphylé’ for a bunch of grapes indicating the cell arrangement, coccus originate from 
the Greek word ‘kókkos’ means berry or grain indicating the cell shape and aureus comes from 
‘aureus’ meaning golden in Latin for the yellow/golden pigmentation of the colonies. The 
pigmentation is caused by carotenoids that protect the bacterium against oxidants and are therefore 
also considered as virulence factors (see section 1.1.3, [1]). The spherical S. aureus cells have a 
diameter of approximately 0.7-1.2 µm (Figure 1). The S. aureus cell is composed of cytoplasm 
surrounded by the cell membrane, a thin periplasmic space and a thick cell wall, and for some strains a 
polysaccharide capsule [2,3]. The cell wall is composed of a thick peptidoglycan layer (see section 
1.2.1) that is decorated by covalently attached wall teichoic acids (see section 1.4) and drawn through 
by lipoteichoic acids anchored in the cytoplasmic membrane [4,5]. Another component connected to 
the peptidoglycan layer are cell surface proteins including adhesive proteins such as protein A, 
fibronectin binding protein or clumping factor A (see section 1.1.3, [6]). The capsule of S. aureus is 
characterised by typing in eleven microcapsular polysaccharide serotypes of which type 5 and type 8 
are most commonly found in clinical isolates [7]. The main function of the cell envelope is to protect 
the bacteria from its high tugor pressure and maintains the cell shape [8]. 
 
 
 
 
 
 
 
Figure 1: Scanning electron microscopy of S. aureus [9] and S. aureus colonies on sheep blood agar. 
 
S. aureus is a facultative anaerobe that is able to grow by both generating energy by aerobic 
respiration or by fermentation yielding mainly in lactic acid formation. A biochemical characteristic 
that allows differentiation of Staphylococci from other Gram-positive cocci, like Streptococci, is their 
capability to hydrolyse hydrogen peroxide classifying them as catalase-positive. S. aureus produce 
coagulases that differentiate them from other coagulase-negative Staphylococci species such as 
1 µm 
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Staphylococcus epidermidis. Both catalase and coagulase are virulence factors as described below in 
section 1.3.3. Differentiation of strains within the species of S. aureus for epidemiological purpose is 
mainly done by three state-of-the-art methods: i) multi locus sequence typing (MLST) that types 
strains by sequencing and assigning of alleles of seven housekeeping genes (carbamate kinase (arcC), 
shikimate dehydrogenase (aroE), glycerol kinase (glpF), guanylate kinase (gmk), phosphate 
acetyltransferase (pta), triosephosphate isomerase (tpi) and acetyl coenzyme A acetyltransferase (yqiL)) 
to different sequence types [10]; ii) spa typing differentiates strains by sequencing of the hyper 
variable part of the gene encoding protein A [11,12]; iii) pulsed field gel electrophoresis (PFGE) of 
SmaI digested chromosomal DNA results in strain specific band patterns of about ten to twenty bands 
of different sizes and the method is still considered the gold standard for differentiating S. aureus 
strains [13,14]. Other less commonly used typing methods include coagulase typing [15], agr typing 
[16,17], typing of the staphylococcus cassette chromosome mec (SCCmec) element (see section 
1.2.2.2, [18,19]) and the detection of present or absence of certain toxins such as Panton-Valentine 
leukocidin (PVL) and the toxic shock syndrome toxin (TSST-1) [20]. 
1. 1. 2   Prevalence and infections 
S. aureus is part of the human normal flora predominantly of the anterior nares and of the skin. On 
average 20% of human population are persistent S. aureus carriers that are always colonised and 60% 
of the population carry S. aureus transiently, called intermediate carriers [21]. S. aureus is an 
opportunistic pathogen and colonisation is generally harmless for healthy individuals; nevertheless, 
S. aureus carriage increases the risk for S. aureus infections [22]. The reservoir of S. aureus on the 
skin and in the nose can become problematic if the natural defence is impaired by immune deficiency, 
injuries of the skin or implantation of biomedical devices that may result in people getting infected by 
either their otherwise commensal S. aureus strain or from an external S. aureus source [21]. Certain 
endemic and especially virulent strains are also reported to cause infections in healthy individuals with 
no obvious risk factors [23].  
 
S. aureus is besides being part of the normal flora a dangerous pathogen and a major cause of both 
community-acquired and nosocomial infections. Nosocomial infections include skin and soft tissue 
infections, such as bullous impetigo, abscesses, furunculosis and staphylococcal scaled skin syndrome, 
but also more severe infections like catheter-associated bacteraemia, ventilator-assisted pneumonia or 
deep-seated infections like meningitis, endocarditis or osteomyelitis. A recent national wide study in 
Switzerland identified S. aureus as the most frequent cause of surgical site infections [24]. 
Community-acquired infections are mainly skin and soft tissue infections and infections of the 
respiratory tract. This infection can become severe or even life-threatening when caused by especially 
virulent strains resulting in necrotizing fasciitis or necrotizing pneumonia [25]. Today, the majority of 
community associated infections are caused by endemic methicillin resistant strains such as USA300 
or EMRSA-16 as also discussed in section 1.2.2.  
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1. 1. 3   Virulence factors 
S. aureus is well equipped with a whole arsenal of virulence factors allowing them to infect different 
tissues and to evade immune defence mechanisms (Figure 2, [6]). The combination of virulence 
factors a strain possesses and their expression levels defines the strains pathogenic potential. However, 
since S. aureus is an opportunistic pathogen, the success is also strongly dependent on the host 
conditions [26]. 
 
To cause an infection a pathogen must in a first step be able to attach to host cells. S. aureus contain 
many different adhesins that enable attachment to host cells, either directly by surface factors 
classified as ‘microbial surface components recognising adhesive matrix molecules’ (MSCRAMMs) 
[27] or indirectly by secreted factors summarized as ‘secretable expanded repertoire adhesive 
molecules’ (SERAM) [28]. These factors include among other fibronectin binding proteins (FnbpA 
and FnbpA), collagen binding proteins (Cna), clumping factors (ClfA and ClfB), the plasma-sensitive 
surface protein (Pls), protein A (SpA), coagulase (Coa) and the extracellular adhesive protein (Epa). 
Besides attachment to host tissues and surfaces of biomedical devices, about 45% to 70% of S. aureus 
strains are able to form biofilms that protects the bacteria from the host immune system and antibiotics 
[29]. 
 
In a next step, the bacteria must be able to invade the host tissue and to acquire nutrients. S. aureus 
secrete various proteins or exotoxins that allow lysis of host cells such as the haemolytic toxins, α-
haemolysin, β-haemolysin, δ-toxin, γ-haemolysin and Panton-Valentine leukocidin (PVL), proteases, 
lipases, hyaluronidases and nucleases [23,25]. 
 
In parallel, the bacteria need to persist against the host immune system. An overview of the S. aureus 
virulence factors with a special focus on immune evasion is shown in Figure 2. S. aureus can inhibit 
the immune response at different steps. The recruitment of phagocytes is inhibited by the chemotaxis 
inhibitory protein of S. aureus (CHIPS) that binds to the leukocyte receptors C5a and N-formyl 
peptides blocking thereby the receptors of chemoattractants [30]. Phagocytes can be lysed by pore-
forming toxins like γ-haemolysin or PVL. The complement system is inhibited by the extracellular 
fibrinogen-binding protein (Efb) that binds to the complement component C3 and by the 
staphylococcal complement inhibitory protein (SCIN) that inhibits C3 convertases [31,32]. Carotenoid 
pigments and the catalase protect from the effectors of immune cells by providing antioxidant shield 
or detoxifying hydrogen peroxide, respectively [1]. Protein A prevents recognition of S. aureus by 
phagocytes by decorating the S. aureus surface with host antibodies through binding of the Fc domain 
of the immunoglobulins. Opsonisation is also limited by the polysaccharide capsule by the fibrinogen 
binding clumping factor and by poly-N-acetylglucosamine (PNAG) [33,34]. The staphylokinase (SAK) 
can activate the conversion of plasminogen (PG) to active plasmin that degrades the opsonin of the 
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complement system (C3b) and human immunoglobulin G (IgG) [35]. Positive charge modification of 
the cell envelope, by D-alanylation of teichoic acids (dlt operon) or transfer of L-lysine to membrane 
lipid phosphatidylglycerol resulting in lysyl-phosphatidylglycerol (MprF), protects from human 
cationic antimicrobial peptides [36-38]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Overview of S. aureus virulence factors with focus on the mechanisms of innate immune resistance. 
Abbreviations are explained in the main text. Adapted from  [6]. 
 
Another strategy of S. aureus to overcome the immune system is hyper activation of the immune 
system through superantigens. The T-cell response is excessively und unspecificially activated by 
binding of superantigens directly to MHC class II molecule and the T-cell receptor. The resulting 
activation of an abnormally high number of T-cells leads to massive release of proinflammatory 
cytokines and recruitment of B- and T- cells to the site of infection that can lead to a shock [39]. 
Superantigens are the toxic shock syndrome toxins (TSST) or enterotoxins (SEA-SEH) that are 
causing agents of the toxin mediated diseases toxic shock syndrome and food poisoning, respectively 
[40]. 
 
1. 1. 4   Genome and mobile genetic elements  
The genome of S. aureus is composed of one circular chromosome that has a size of about 2.8 Mb and 
a low GC content of approximately 33%. The first complete genome sequences of the strains Mu50 
and N315 were published in 2001 [41]. To date, complete genome sequences for 43 S. aureus strains 
are available in the NCBI Genome database. Much more data is accessible as incomplete genome 
scaffolds or contigs from next generation sequencing projects of hundreds of strains. The genome of 
S. aureus contains about 2700 protein encoding genes plus structural and regulator RNAs. Of these 
genes about 75% are classified as core genome conserved in the vast majority of the strains (>95%) 
1 Introduction 
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[3]. The core genome is mainly composed of genes encoding essential metabolic and regulatory 
proteins as well as surface proteins. The remaining 25% is called accessory genome, genetic material 
that is dispensable and only present in about 50% of the strains. This includes mobile genetic elements, 
such as pathogenicity islands, genomic islands, prophages, transposons, insertion sequences and 
chromosomal cassettes like the SCCmec element ([3,42], see section 1.2.2.2). Besides the 
chromosome, S. aureus can also carry genetic information on plasmids that is also counted to the 
accessory genome [42].  
 
1. 2  Antibiotics and antibiotic resistance in S. aureus 
S. aureus is able to rapidly adapt to changes in the environment including exposure to antibiotics and it 
is able to develop resistance to virtually all antibiotics. Especially, multi-resistant strains are limiting 
treatment options resulting in impaired treatment outcomes. There are three general principles by 
which a bacterium can become resistant to antibiotics. First, the antibiotic can be inactivated or 
modified; second, the target of the antibiotic can be altered; and third, the accumulation of the 
antibiotic can be prevented by efflux or uptake inhibition. These three principles can be achieved by 
mutation in the chromosome, accumulation of additional genetic material or by up-regulation or down-
regulation of certain pathways [43]. 
 
Antibiotic targets need to be enzymes or pathways that are unique to prokaryotes to prevent 
cytotoxicity for human cells and to limit side effects. The first antibiotic penicillin, accidentally 
discovered by Alexander Fleming in 1928, inhibits cell wall synthesis [44]. The discovery of penicillin 
provided the basis for the development of the diverse class of very effective beta-lactam antibiotics 
including carbapenems and cephalosporins and it is still the most frequently used class of antibiotics.  
1. 2. 1   Cell wall biosynthesis as an antibiotic target 
The cell wall of S. aureus is made of peptidoglycan (also called murein), a heteropolymer that consists 
of alternating N-actetyl muramic acid (MurNAc) and N-acetyl glucosamine (GlcNAc) connected by 
short peptide chains [5]. Omitting the biosynthesis of precursors, the first step of peptidoglycan 
synthesis is the addition of phosphoenolpyruvate (PEP) to uridine diphosphate (UDP) GlcNAc 
catalysed by the UDP-N-acetyl-glucosamine-3-enolpyruvyl transferase MurA resulting in UDP-N-
acetylenolpyruvyl-glucosamine (UDP-GlcNAcEP) as shown in Figure 3. Fosfomycin inhibits this very 
first step by covalent modification of the enzyme MurA [45]. MurB then catalyses NADPH-dependent 
reduction of UDP-GlcNAcEP to the UDP-MurNAc followed by attachment of an L-alanine, a D-
glutamate and an L-lysine to UDP-MurNAc by the enzymes MurC, MurD and MurE, respectively 
(Figure 3, [46]). D-cycloserine inhibits the next step, the addition of two D-alanines to the 
peptidoglycan precursor by inhibiting both the alanine racemase and the D-alanine:D-alanine ligase A 
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Figure 3: Schematic representation of the enzymatic steps involved in S. aureus cell wall synthesis and the 
targets of cell wall active antibiotics. Inhibition of enzymatic steps is indicated by blocked arrows, cleavage of 
the pentaglycine bridge by lysostaphin and disruption/depolarization of the membrane by daptomycin is 
indicated with arrows. Adapted from [46,47]. 
 
[47]. In the following step, the peptidoglycan precursor is attached to the undecaprenyl-pyrophosphate 
lipid anchor (also called C55-isoprenyl pyrophosphate or bactoprenol) by the transferase MraY 
resulting in the intermediate lipid I. This transfer by MraY is inhibited by tunicamycin [48,49]. 
Tunicamycin inhibits also the first enzyme of wall teichoic acid biosynthesis, the attachment of an 
UDP-GlcNAc to the undecaprenyl-pyrophosphate lipid carrier by TarO, even with a higher affinity 
(see section 1.4, [50]). Next, the glycosyl transferase MurG attaches an UDP-GlcNAc to the lipid 
bound precursor resulting in the intermediate lipid II. In the following, the pentaglycin bridge is 
formed by the non-ribosomal peptidyltransferases FemX, FemA and FemB resulting in the completed 
lipid anchored peptidoglycan monomer [51-53]. This final lipid II is flipped to the outside of the cell 
by a yet unknown enzyme [5]. Bacitracin inhibits cell wall biosynthesis by forming a metal dependent 
complex with the lipid carrier undecaprenyl-pyrophosphate and thereby preventing dephosphorylation 
of undecaprenyl-pyrophosphate, the recycling of the lipid carrier of cell wall synthesis [54,55]. The 
first step of the polymerisation of the precursors is transglycosylation by the bifunctional penicillin-
binding protein 2 (PBP2). Transglycosylation is inhibited by flavomycin (also called moenomycin) 
through binding of the transglycosylase domain of PBP2 and thereby preventing the incorporation of 
the peptidoglycan subunits into the peptidoglycan matrix. Glycopeptide antibiotics such as 
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vancomycin or teicoplanin bind to the D-ala-D-ala of the lipid II shielding the substrate of 
transglycosylation and transpeptidation [56]. The final cross-linking of the peptidoglycan subunits by 
transpeptidation is catalysed by the four PBPs (PBP1-4). Tanspeptidation is inhibited by the above 
mentioned beta-lactam antibiotics such as oxacillin and penicillin that bind the transpeptidase active 
domain of penicillin-binding proteins (PBPs) [57]. Different beta-lactam antibiotics were detected to 
inhibit all PBPs, like ampicillin and oxacillin or specifically inhibit one PBP such as imipenem and 
meropenem (PBP1 selective), cefotaxime and ceftriaxone (PBP2 selective), cefaclor (PBP3 selective) 
and cefoxitin (PBP4 selective) [58-62]. 
 
Even though daptomycin acts primarily on the membrane it was also suggested to indirectly inhibit 
peptidoglycan synthesis and to act synergistically with PBP1 inhibiting beta-lactam antibiotics [58,63]. 
The current model of the mode of action proposes that daptomycin is delivered to the membrane in 
form of micelles that possibly further oligomerise leading to potassium efflux and cell death [64-66]. 
Besides antibiotics, also the zinc metalloenzyme lysostaphin from Staphylococcus simulans targets 
specifically the cell wall peptidoglycan of S. aureus by cleaving the pentaglycine cross-linking bridge 
[67]. 
1. 2. 2   Methicillin resistant S. aureus 
The discovery of penicillin and the establishment of penicillin as agent for treatment of infections 
during the Word War II resulted in a drastic decrease of the lethality of S. aureus infections and 
bacterial infections in general. However, soon after the establishment of penicillin treatment, penicillin 
resistant S. aureus strains emerged limiting the effectiveness of penicillin treatment [68]. Penicillin 
resistant S. aureus have acquired a usually plasmid encoded beta-lactamase that cleaves the lactam 
ring of penicillin; and already towards the end of the 1950s 80% of S. aureus were resistant to 
penicillin [69]. Therefore, the semi-synthetic penicillinase resistant beta-lactam methicillin was 
developed and approved for treatment in 1959. Today, the more stable methicillin analogue oxacillin 
or other beta-lactam antibiotics are used in clinics. Within one year of the introduction of methicillin, 
the first methicillin resistant S. aureus (MRSA) were reported [70]. MRSA have acquired an 
additional penicillin-binding protein PBP2a that allows cell wall synthesis in presence of methicillin 
(see section 1.2.2.2). Infections with MRSA are problematic and difficult to treat, in particular, if the 
MRSA strains have acquired resistance to other antibiotic classes resulting in multi-drug resistant 
strains (see sections 1.2.2.2). The treatment of infections with last resource antibiotics is not only cost 
intensive for the health care system but it is also often less efficient, accompanied by severe side 
effects and it drives the selection for new resistances [71]. 
1. 2. 2. 1  Epidemiology of MRSA 
The number of infections caused by methicillin resistant S. aureus (MRSA) is still increasing. A 
national wide study of the USA in 2010 detected that on average 41 in 1000 hospitalized patients were 
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colonised and 25 in 1000 hospitalized patients were infected with MRSA [72]. The overall MRSA 
incidences including both infection and colonisation in hospitals increased since 2006 from 46 in 1000 
patients to 66 in 1000 patients in 2010 [72]. However, the number for invasive life-threatening MRSA 
infections declined from 2005 to 2008 in the USA [73]. The proportion of MRSA given relative to the 
total S. aureus incidences in the USA was 66.4% in 2009 [74]. In Europe, the situation is better with 
lower percentage of MRSA in most countries. However, MRSA rates differ a lot between geographic 
areas with an increase from north to south and rates can reach over 50% of the total S. aureus infection 
in certain countries as reported by European Center for Disease Prevention and control (ECDC) in 
2011 (Figure 4). The reasons for the higher percentage of MRSA in southern countries are not 
completely understood. However, a correlation to the higher number of antibiotic prescriptions and 
less efficient precautions and interventions, for example screening and isolation of patients colonized 
with MRSA in hospitals, is suggested [75,76]. The percentage of MRSA infection in Switzerland was 
10.2% in 2012 (Swiss Centre for Antibiotic Resistance, www.anresis.ch), comparable to the northern 
neighbouring countries. The emergence of so-called community-associated (CA-) MRSA over the last 
two decades clearly contributed to the increase of MRSA numbers. In the USA 45% of all MRSA 
were classified as CA-MRSA strains in 2009, such as the typical endemic strains CA-MRSA USA300 
(see section 1.2.2.3, [74]). Interestingly, almost all MRSA clones worldwide belong to only five clonal 
complexes (CCs): CC5, CC8, CC22, CC30 and CC45 [23]; a clearly limited diversity compared to 
methicillin sensitive S. aureus (MSSA) that are more heterogeneous [69]. 
 
 
 
Figure 4: Prevalence of MRSA infections in Europe according to the European Centre for Disease Prevention 
and Control in percentage (%) of MRSA relative to the total number of S. aureus infections in 2011. Figure from 
www.ecdc.europa.eu. 
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1. 2. 2. 2  The staphylococcal cassette chromosome mec 
Methicillin resistance is encoded on a mobile genetic element named staphylococcal cassette 
chromosome mec (SCCmec). The actual resistance gene mecA encodes an alternative penicillin-
binding protein PBP2a with lower affinity for beta-lactams than the endogenous PBPs, allowing cell 
wall synthesis in presence of beta-lactam antibiotics. The size of SCCmec elements varies between 21 
kb to 69 kb, though larger mosaic SCCmec elements exist. SCCmec elements consist of the mec gene 
complex, the cassette chromosome recombinase (crr) gene complex and so-called J region (joining or 
junkyard regions), defined as regions other than the mec or ccr complex [19]. The composition of the 
mec gene complex varies and a complete complex is made of the resistance gene mecA, the repressor 
mecI, the signal transducer mecR1, the antirepressor mecR2 (see section 1.2.2.4) and different insertion 
sequences (IS). The mec gene complex is according to its composition assigned to five different 
classes A, B, C1, C2 and E (Table 1, [18,19,77]). The presence or absence of the recently discovered 
mecR2 has not been considered for SCCmec typing up to now. mecR2 is generally present in the 
SCCmec types containing functional mecR1-mecI genes (SCCmec types II, III, VIII and XI) and 
absent in the other types [77]. The ccr gene complex allows the site specific integration of the 
SCCmec element into the S. aureus chromosome at the attachment site located at the 3’ end of orfX 
(encoding a ribosomal methyltransferase of the RlmH type, [78]). There are eight types of ccr gene 
complexes composed of combinations of three phylogenetically distinct ccr genes with less than 50% 
sequence similarity (ccrA, ccrB and ccrC) and of subtypes of ccrA and ccrB with less than 85% 
nucleotide identity. So far, there are eleven SCCmec types classified according to the type of the crr 
complex and the mec gene complex (Table 1). 
 
Table 1: SCCmec types of S. aureus. 
SCCmec 
types 
ccr gene 
complexes mec gene complexes strains examples 
I 1 (A1B1) B (IS431-mecA-∆mecR1-IS1272) NCTC10442, COL 
II 2 (A2B2) A (IS431-mecA-mecR1-mecI) N315, Mu50, Mu3, MRSA252, JH1, JH9 
III 3 (A3B3) A (IS431-mecA-mecR1-mecI) 85/2082 
IV 2 (A2B2) B (IS431-mecA-∆mecR1-IS1272) 
MW2, 8/6-3P, 81/108, 2314, cm11, 
JCSC4469, M03-68, EMRSA-15, 
JCSC6668, JCSC6670, USA300 
V 5 (C1) C2* (IS431-mecA-∆mecR1-IS431) WIS (WBG8318), TSGH17, PM1, 
VI 4 (A4B4) B (IS431-mecA-∆mecR1-IS1272) HDE288 
VII 5 (C1) C1 (IS431-mecA-∆mecR1-IS431) JCSC6082 
VIII 4 (A4B4) A (IS431-mecA-mecR1-mecI) C10682, BK20781 
IX 1 (A1B1) C2* (IS431-mecA-∆mecR1-IS431) JCSC6943 
X 7 (A1B6) C1 (IS431-mecA-∆mecR1-IS431) JCSC6945 
XI 8 (A1B3) E (blaZ-mecALGA251-mecR1LGA251-mecILGA251) LGA251 
* The two IS431 are arranged in opposite direction. Table adapted from www.sccmec.org and [18]. 
 
In addition to methicillin resistance, the SCCmec is a hotspot for integration of plasmids and 
transposons encoding genes conferring resistance for example to kanamycin, erythromycin and 
clindamycin, tetracycline, mercury (SCCHg or SCCmercury) and cadmium [19,69,79]. SCCmec 
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elements can be linked to genes such as the arginine catabolic mobile element (ACME) and peptide 
toxin genes (PSM-mec) [18].  
1. 2. 2. 3  Hospital-associated versus community-acquired MRSA 
MRSA strains were for a long time restricted to hospitals setting or other areas with high antibiotic 
pressure. This so-called hospital-associated (HA-) MRSA strains carry often the early identified large 
SCCmec element of type I, II and III (see section 1.2.2.2) that have been acquired only by a limited 
number of clones [69,80]. Initially, MRSA showed a heterogeneous resistance profile, where only a 
small subpopulation can survive high beta-lactam concentrations. Over time, however, highly 
homogenously resistant strains evolved that were spreading throughout the hospitals of various 
countries from the 1970 onwards. Examples of early endemic MRSA clones are the Iberian clone 
(ST247, SCCmec type I), the Brazilian/Hungarian clone (ST239, SCCmec type III), the New 
York/Japan clone (ST5, SCCmec type II) and EMRSA 16 (ST32, SCCmec type II) (reviewed in 
[80,81]). These highly resistant HA-MRSA strains have often a reduced growth rate compared to 
MSSA strain that could be one explanation for their restriction to areas with high antibiotic pressure 
[82-85]. The reasons for the decreased fitness and competitiveness are suggested to result from the 
high methicillin resistance level, the maintenance of about 50 kb additional genetic material and from 
additional resistance determinants like tetracycline, kanamycin, erythromycin and clindamycin genes 
resulting in multi-drug resistant phenotype. 
 
Over the last two decades, MRSA started to emerge into the community. These so-called CA-MRSA 
showed increased fitness and virulence leading to infections in individuals without obvious risk factors 
[23]. The methicillin resistance level of CA-MRSA is generally lower compared to HA-MRSA strains 
and CA-MRSA strains often show a heterogeneous resistance profile that nonetheless normally results 
in beta-lactam treatment failures [23,25]. CA-MRSA strains mainly carry smaller more recently 
discovered SCCmec elements, predominantly type IV but also type V. The decreased size of these 
elements and the general absence of additional resistance genes are suggested to reduce fitness costs 
and thereby possibly increase fitness of these strains compared to HA-MRSA [83,86]. It was also 
suggested that the AMCE element carrying an arginine deiminase gene often associated with SCCmec 
IV could increase fitness of the strains [86]. However, the exact reasons and mechanisms responsible 
for the differences in fitness and methicillin resistance of HA-MRSA and CA-MRSA remain unclear.  
 
Increased virulence of CA-MRSA was for a long time connected to the presence of a highly potent 
cytotoxcin, the Panton-Valentine leukocidin (PVL), which is also used to differentiate between HA-
MRSA and CA-MRSA. PVL is a two-component pore forming toxin that is immuno-resistant, 
cytotoxic to monocytes and polymorphonuclear neutrophils and encoded in the genes lukS-PV and 
lukF-PV located on different prophages [87,88]. The relevance of PVL for the increased virulence of 
CA-MRSA strains is still debated and CA-MRSA strains lacking PVL can also cause severe infections 
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and become endemic as for example observed for the Australian CA-MRSA [89]. Neutrophils from 
different animals were recently discovered to vary in their sensitivity to PVL. PVL is more active 
against human and rabbit neutrophils and less leukocidal for murine, rat or simian neutrophils 
explaining the confusing and contradictory results for PVL importance in animal infection models [90]. 
A current opinion from a systematic literature review is that PVL increases virulence of strains in skin 
and soft tissue infections but has only minor influence on pneumonia, musculoskeletal infections and 
bacteraemia [91]. Though, the importance of PVL in pneumonia is still highly debated today [92,93].  
 
Another explanation for the increased virulence of CA-MRSA is the elevated expression of virulence 
factors of the core genome like α-toxin or so-called phenol-soluble-modulins (PSM) [25,94]. PSM are 
very potent against human neutrophils and are released at higher concentrations from CA-MRSA than 
from HA-MRSA and are therefore suggested to be a key element in increased virulence of CA-MRSA 
[95].  
 
Since a few years, CA-MRSA emerge into hospital settings and especially endemic CA-MRSA like 
USA300 are causing increased incidences of hospital onset CA-MRSA infections [96]. In Europe, 
USA300 is also detected in hospitals but the most frequently observed CA-MRSA belong to ST80 and 
spa type t044 [71]. Nosocomial infections by CA-MRSA limit the original epidemiological 
differentiation and a genotype based definition was suggested for HA-MRSA and CA-MRSA [97].  
 1. 2. 2. 4  Factors influencing the methicillin resistance level 
The methicillin resistance is dependent on regulation of the resistance determinant mecA. Initially, 
regulation of mecA expression was claimed to be controlled by the two-component system composed 
of mecR1-mecI, encoding a sensor-inducer and a repressor, respectively [98]. Recently, a third 
component, the anti-repressor MecR2, was discovered to be involved in mecA regulation and a model 
for three-component regulation is suggested [77]. Beta-lactam antibiotics bind to the extracellular 
sensor domain of MecR1 that leads to autocatalytic cleavage resulting in activation of the 
cytoplasmatic inducer domain of MecR1. The activated inducer domain of MecR1 directly or 
indirectly cleaves the dimers of the repressor MecI allowing transcription of mecA and of the mecR1-
mecI-mecR2 operon. MecR2 interacts with MecI and promotes the proteolytic cleavage of MecI that is 
essential for the mecA induction. In absence of beta-lactams MecI dimers are bound to the mecA 
promoters repressing transcription. Due to the structural and functional similarity of MecI to the 
repressor BlaI of the beta-lactamase gene blaZ, both repressors can bind to the mecR1-mecI-mecR2 
and blaZ-blaR1-blaI promoter regions [99]. It is also suggested that the presence of bla regulators 
stabilizes mecA expression; this is supported by the fact that >95% of MRSA carry a beta-lactamase 
[100]. Arede et al. suggest that the mecA expression is optimized by formation of MecI::BlaI 
heterodimers that have lower affinity to the mecA promoter resulting in derepression of the mecA 
transcription [101]. The MecI, MecR1 and MecR2 regulation system is often only partially present or 
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mutated in clinical strains as listed in the SCCmec types (Table 1). Only the SCCmec types II, III, VIII 
and XI carry an intact mecR1-mecI regulatory system that generally contains also the anti-repressor 
MecR2 [77]. There exist highly resistant strains constitutively expressing mecA due to the absence of 
the MecI repressor, as for example the strain COL [19,102]. 
 
However, the level of methicillin resistance is not only defined by mecA expression levels but it is also 
dependent on the genetic composition of a strain and on specific genetic factors influencing resistance 
[103-105]. There is no direct correlation between the mecA transcription level and the beta-lactam 
resistance level [104,106]. Factors influencing methicillin resistance, previously called fem (factors 
essential for methicillin resistance) or aux (auxiliary) genes, are often directly or indirectly involved in 
cell envelope biosynthesis and turnover [107]. The majority of these factors do not directly interfere 
with mecA expression and influence often also intrinsic resistance to methicillin in MSSA strains 
[103,104]. Examples are the cell wall biosynthesis enzymes like FemABX [108], GlmM [109], GlmS 
[110], MurE [111], MurF [112], PBP2 [113], PBP4 [114] or wall teichoic acid biosynthsis enzymes 
including TarO/TagO [115], the dlt operon [116] and the predicted wall teichoic acid ligase MsrR 
[117]. Factors with indirect or with no obvious connection to the cell envelope include regulators like 
SigB [102], SpoVG [118], agr [119], SarA [119], XdrA [120], CcpA [121], SecDE [122] and the two-
component system VrasR ([123,124], see section 1.3.2). Recently, the nucleotide second messengers 
c-di-AMP and (p)ppGpp were identified to influence beta-lactam resistance as well ([125,126], see 
section 1.5).  
 
1. 3  Two-component systems of S. aureus 
1. 3. 1   Overview of the two-component systems of S. aureus 
For the survival of bacteria it is crucial to respond to changes in the environment. One mechanism by 
which S. aureus senses exogenous signals and respond to the stress stimuli by cellular adaption are 
two-comment systems (TCS). Signal transduction is facilitated by the phosphor transfer from a 
membrane located senor kinase to the response regulator that then generally regulates genes on the 
transcriptional level. Dephosphorylation of the regulator shuts down the regulatory response. The best 
characterised TCS of S. aureus is the agr system that globally regulates virulence and toxin expression 
in a growth phase-dependent and cell density dependent manner (quorum sensing) (reviewed in [127]). 
S. aureus possesses 16 chromosomally encoded TCS that are summarized in Table 2. Only the WalKR 
TCS is essential and at least five TCS are reported to influence antibiotic resistance: VraSR, BecRS, 
WalKR, LytRS and GraSR; they have effects on beta-lactam, bacitracin and/or glycopeptide resistance 
(Table 2, [128-130]). In addition to the chromosomally encoded TCS S. aureus can acquire TCS 
encoded on mobile genetic elements, such as the VanSR, BlaR1-BlaI and MecR1-MecI, involved in 
regulation of vancomycin and beta-lactam resistance, respectively (section 1.2.2.4 [46]). 
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  Table 2: Two-component systems of S. aureus 
Name ORF no. function/predicted role/connection to antibiotic 
resistance 
References 
AgrAC MW1962/3 accessory gene regulator, regulation of virulence, quorum 
sensor 
[127] 
VraSR MW1824/5 
regulation of cell wall biosynthesis enzymes and autolysins, 
protection to cell wall stress including various cell wall 
active antibiotics 
[124,131,132] 
LytSR MW0236/7 
regulation of autolysins and sensing of alteration of 
membrane potential, influence on penicillin tolerance and 
resistance to cationic antimicrobial peptides 
[133,134] 
SaeRS MW0667/8 regulation of virulence factors [135] 
WalKR* MW0018/9 regulation of autolysins, virulence genes, methicillin 
resistance and glycopeptide intermediate resistance [128,136] 
ArlRS MW1304/5 regulation of virulence factors and autolysin [137] 
SrrAB MW1445/6 regulation of virulence, respiratory response, anaerobic genes [138] 
PhoPQ MW1636/7 alkaline phosphatase synthesis response regulator [130] 
KdpDE MW2002/3 regulation of virulence, potassium transport [139] 
HssRS MW2282/3 regulation of response to heme (heme transporter HrtAB) [140] 
NreBC MW2313/4 Regulation of dissimilatory reduction and transport of nitrate 
and nitrate, oxygen-responsive [141] 
Aps/GraSR MW0621/2 regulation of dlt and mprF, influence on resistance to 
vancomycin, gentamicin, nisin and defensins [142,143] 
BceRS MW2544/5 regulation of two transporters connected to bacitracin 
susceptibility [129] 
SA0215/6 MW0198/9 uncharacterised TCS [130] 
SA1158/9 MW1208/9 uncharacterised TCS [130] 
SA1666/7 MW1789/90 uncharacterised TCS [130] 
  * Essential TCS 
1. 3. 2   The VraSR-dependent cell wall stress stimulon 
The first layer of protection from environmental stress situations is the thick cell envelope of S. aureus. 
Accordingly, adaptations to cell envelope stress in form of stress responses are critical for the survival. 
S. aureus has one cell wall stress stimulon (CWSS), a set of genes that is regulated by the VraSR two-
component system [124,132,144]. The CWSS is induced by cell wall active antibiotics or by depletion 
of genes essential for cell wall biosynthesis like MurA, MurZ, MurB, MurF and PBP2 [131,145,146]. 
Although VraSR was named after its role in vancomycin resistance (vancomycin resistance 
associated), deletion of VraSR also decreases resistance to methicillin, fosfomycin, bacitracin and 
other cell wall antibiotics, indicating a crucial role of the stress response in various resistance 
phenotypes [147]. The core genes regulated by VraSR comprise a regulon of about 50 genes [131]. 
The majority of these genes encode proteins linked to cell envelope biosynthesis such as: MurZ 
(MurA isozyme), involved in the early steps of cell wall biosynthesis [145,148]; PBP2, a penicillin-
binding protein (PBP) with both transglycosylation and transpeptidation activity [113,148]; SgtB, 
involved in transglycosylation [148,149]; FmtA, a PBP with low affinity to beta-lactams [150]; the 
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predicted autolysins Atl and SA0424 [151] as well as the predicted wall teichoic acid ligases MsrR, 
SA0908 and SA2103 ([152,153], see also section 1.5). Up-regulation of CWSS genes directly linked 
to cell envelope synthesis and down-regulation of autolysins is suggested to protect against cell 
envelope stress [154-156]. This hypothesis is supported by increased cell wall thickness of both 
clinical glycopeptide intermediate resistant S. aureus (GISA) strains carrying VraS mutations and 
laboratory strains artificially over-expressing VraS resulting in an increased CWSS expression [157]. 
Besides well characterized genes, there are several genes of unknown or poorly characterised 
functions in the VraSR regulon, including the highest up-regulated gene sas016 (also called vraX) of 
unknown function [132,158]. The exact composition of the VraSR regulon is strongly dependent on 
the induction conditions and the experimental procedures applied. 
 
The signalling by VraSR consists of a typical TCS mechanism as described above (see 1.3.1.). An 
unknown signal for cell wall stress triggers the intramembrane histidine kinase VraS to activate the 
response regulator VraR by phosphorylation. In the absence of a stress signal, VraR is deactivated by 
VraS dependent dephosphorylation. Analysis of the phosphorylation properties revealed that VraSR 
might respond very fast in vivo [159]. In depth analysis of the DNA-binding properties of VraR to the 
promoter of the vra operon identified the VraR DNA-binding motif ACTaaAGTaTGAacaTCA 
[159,160]. Also in silco analysis of promoters of the VraSR regulon suggested the VraR DNA-binding 
motif TxxxxCxxxxGxxxxA [161] that is partially overlapping with the above stated motif identified 
by DNA-binding analysis of the vra operon promoter [159,160].  
 
The VraSR TCS is homologous to the cell envelope stress sensor system LiaSR (or CesRS) present in 
most Firmicutes including Bacillus subtilis [162], Streptococcus mutans [163], Streptococcus 
pneumonia [164], Enterococcus faecium [165] as well as Lactococcus lactis [161]. Even though all 
these systems respond to cell envelope stress including an overlap of inducing antibiotics, the 
composition and size of their respective regulons are diverse, indicating a species specific function and 
relevance [144]. In B. subtilis and S. mutans a third component, LiaF, was recently discovered to 
repress LiaSR signalling under non stress conditions. Due to the crucial role of LiaF for signalling it 
was suggested that the LiaSR and homologous TCS to LiaSR are in fact a three-component systems 
(LiaFSR) [166]. VraSR is suggested to form a three component system including vraT (sa1702, 
previously called yvqF) that is encoded directly upstream of vraS in the four-cistron autoregulatory 
VraSR operon (vraU-vraR-vraS-vraR). The function of the LiaF homologue VraT, however, is still 
debated. McCallum et al. suggest that VraT actives VraSR in S. aureus, the opposite effect of the 
repressor LiaF in B. subtilis [147]. Their study detected that VraT interacts with VraS as well as that in 
a vraT deletion mutant both the resistance to cell wall active antibiotics and the expression of the 
CWSS are decreased, similar to VraS and VraR mutants [147]. Contradictory, a study analysing 
vancomycin intermediate resistant S. aureus (VISA) suggested that VraT functions as repressor 
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similar to LiaF [157]. A point mutation in vraT in a VISA strain increased vancomycin resistance and 
CWSS expression that was complemented by introducing the wild type VraT supporting a repressor 
function [157]. However, there was no direct proof of a VraT repressor function and a gain of function 
mutation could explain the same observations. The most recent study supports a CWSS inducing role 
of VraT confirming the results from McCallum et al. [157,167]. Transcription analysis of a vraT 
mutant showed overlapping up- and down-regulation patterns to a vraS mutant, and oxacillin 
resistance and CWSS expression was reduced in the vraT mutant. The function of the product of the 
forth gene on the vra operon VraU (previously called orf1) remains elusive, but a direct connection to 
VraSR seems unlikely since a vraU mutant did neither influence oxacillin resistance nor expression of 
CWSS genes [147,167]. 
 
All findings together confirm a direct involvement of VraT in VraSR signal transduction and support 
the hypothesis of a VraTSR three-component system. Although the exact signalling pathway is not 
completely understood, a working model of the VraSR system including VraT is shown in Figure 5. 
Upon an unknown cell wall stress signal VraS phosphorylates VraR. VraT influences the signal 
transduction of the system by interaction with VraS and possibly transmitting the initial stress signal to 
VraS. Phosphorylated VraR regulates expression of VraR regulon genes and autoregulates the 
expression of the vraU-vraT-vraS-vraR operon.  
 
 
 
Figure 5: Working model of VraSR signalling including factor VraT. Black arrows and the black blocked arrow 
indicate transcriptional regulation, the red arrow indicates phosphorylation of VraR by VraS, double-pointed 
arrows indicate confirmed interaction of VraT and VraS; dashed double-pointed arrows indicate possible 
additional interactions or signal transduction pathways. Adapted from [147,167]. 
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1. 4  Wall teichoic acid biosynthesis and the LytR-CpsA-Psr protein 
family 
Wall teichoic acids are anioic glyopolymers that are covalently attached to the peptidoglycan by 
phosphodiester linkage to C6 hydroxyl of the N-acetyl muramic acid. Wall teichoic acids make up to 
60% of the total cell wall mass of Gram-positive bacteria. In contrast to B. subtilis that synthesizes 
ploy(glycerol phosphate) WTA and poly(ribitol phosphate) WTA, S. aureus produces mainly 
poly(ribitol phosphate) WTA [168]. The function of wall teichoic acids is not yet fully understood. 
WTA are found to be involved in protection against harmful molecules and environmental stress; in 
extracellular interactions including adhesion and phage reception; in the stability and permeability of 
the membrane as well as in the control of cation concentration in the cell envelope; and they act as 
scaffold for extracellular enzymes involved in cell wall biosynthesis and turn over [4,168]. WTA are 
required in cell wall biosynthesis to direct autolysin to the septum and protect the other parts of the 
cells from autolysis [169]. 
 
The enzymes TarO and TarA initiate WTA synthesis by transferring UDP linked precursors N-acetyl 
glucosamine (GlcNAc) and N-acetyl mannosamine (ManNAc) to the lipid carrier undecaprenyl-
phosphate (or also called bactoprenol) (Figure 6, [170]). TarO and TarA deletion mutants are viable 
but have impaired adhesion properties and an impaired cell division [171,172]. Deletion of all 
following enzymes in the wall teichoic acid synthesis pathway is so-called synthetic lethal (Figure 5). 
This means that deletion mutants are unable to grow in a wild type background but are viable in a tarO 
or tarA mutant background [173]. A possible explanation for this phenomenon is that the 
accumulation of the intermediates is toxic or that it blocks the lipid carrier required also for cell wall 
biosynthesis [174]. After initiation, the next step of the biosynthetic pathways is addition of two 
glycerol-3-phosphates by TarB and TarF [175]. TarD generates CDP-glycerol, the activated precursor 
for these two steps by TarB and TarF [176]. The actual polymerisation step of ribitol-5-P is catalysed 
by TarL and it is dependent on CDP-ribitol precursor synthesis by TarJ and TarI [175,177,178]. 
Interestingly, there is a duplication of the gene cluster TarIJL in S. aureus and the two different 
variants of TarL were claimed to produce different sizes of poly(ribitol) chains [177]. The flipping of 
the lipid carrier attached precursor from the inside to the outside of the cell is facilitated by the 
transporter TarGH [179]. Even though wall teichoic acids are not essential, the deleterious effects of 
inhibition from the third step onwards make WTA biosynthesis a target for antibiotics. So far, only 
one antibiotic is described to specifically target wall teichoic acid biosynthesis, targocil, which inhibits 
the tranferase TarGH (Figure 5, [50,180]). Tunicamyin inhibits both the cell wall synthesis enzyme 
MarY as described above (Figure 3) and TarO, the latter even with a much higher affinity [173].  
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Figure 6: Schematic representation of the enzymatic steps involved in S. aureus wall teichoic acid (WTA) 
biosynthesis and antibiotics inhibiting WTA biosynthesis. Inhibition of enzymatic steps by antibiotics is 
indicated by red blocked arrows. Nonessential WTA synthesis enzymes are colored green, conditionally essential 
are colored red and the hypothetical step by LCP proteins is colored white. Adapted from [168]. 
 
The very last step of wall teichoic acid synthesis is the attachment of WTAs to the peptidoglycan. This 
final step was for a long time elusive and has only been described by Kawai et al. in B. subtilis in 2011 
[152]. Their study revealed that members of the protein family LytR-CpsA-Psr (LCP), a protein family 
unique to Gram-positive bacteria [181], catalyses the ligation of wall teichoic acids to the 
peptidoglycan in B. subtilis [152]. The role of LCP proteins in other Gram-positive species is only 
partially described by analysis of LCP mutant stains that suggest a function connected to cell envelope 
synthesis [117,153,182-184]. In S. aureus there are three LCP proteins, SA2103, SA0908 and MrsR 
which are partially redundant [153]. Deletion of MsrR decreases methicillin resistance, virulence and 
it results in an impaired cell division [117]. Surprisingly, the LCP triple mutant in S. aureus is viable, 
in contrast to B. subtilis where LCP proteins are synthetic lethal [152,153]. In B. subtilis all three LCP 
genes can only be deleted in a ∆tarO or ∆tarA background that prevents the flux of precursors into the 
synthesis pathways, comparable to other WTA synthesis enzymes that are considered conditionally 
essential [152,153]. Though, the S. aureus LCP triple deletion is not lethal, it causes severe growth 
defects with irregular septum formation, defective cell separation and giant cells and leading to the 
speculation that the S. aureus LCP triple mutant is possibly only viable due to secondary mutations 
[153]. 
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1. 5  Nucleotide second messengers 
Nucleotides such as (p)ppGpp, cAMP, cGMP, c-di-GMP, c-di-AMP or c-di-GMP-AMP are so-called 
second messengers and they are involved in regulation of various cellular processes including 
virulence, biofilm formation, motility and the cell cycle (reviewed in [185]). Quorum sensing 
signalling is known to regulate similar processes and it was suggested that there is an interaction 
between signalling by nucleotide and quorum sensing [186]. Regulation by nucleotides take place at 
all stages from transcriptional and translational to post translational regulation. Nucleotide signalling 
is introduced here by focusing on the nucleotides (p)ppGpp and c-di-AMP that affect antibiotic 
resistance of S. aureus. 
1. 5. 1   The alarmone (p)ppGpp 
The two linear nucleotides guanosine tretraphosphate ppGpp and guanosine pentaphosphate pppGpp 
(summarized as (p)ppGpp) regulate stringent response and are termed ‘alarmones’ that are produced 
rapidly in response to amino acid, phosphate, fatty acid, carbon and iron starvation. (p)ppGpp shuts 
down the proliferating processes of bacteria in response to nutrient limitation for example by 
transcription repression of the proteins synthesis machinery including rRNA, ribosomal proteins and 
translation factors and by up-regulation of stress response mechanisms [187]. There are fundamental 
differences in the molecular mechanism of (p)ppGpp regulation between different species (reviewed in 
[188]). The knowledge of (p)ppGpp signalling in S. aureus is limited, but similar to other bacteria, a 
down-regulation of protein and nucleotide synthesis related genes was detected [189]. The mechanism 
of this down-regulation is unknown but it is suggested that the lowering of the GTP pool in stringent 
response through (p)ppGpp production limits transcription initiation from genes starting with iGTP as 
found in B. subtilis [190,191]. The major pathway in S. aureus for (p)ppGpp-dependent up-regulation 
of genes is the de-repression of the regulator CodY [189]. The CodY regulates mainly genes of the 
nitrogen metabolism but also virulence factors essentially by repression of the agr system [192,193]. 
Additionally, seven genes were detected to respond CodY-independently to (p)ppGpp levels including 
two phenol-soluble-modulins that are cytolytic molecules important for intracellular survival [189]. 
The importance of (p)ppGpp in the virulence of S. aureus is in agreement with similar findings in 
other species [194]. A recent study identified also a direct correlation of the level (p)ppGpp to 
methicillin resistance levels by a yet unknown mechanism [126]. 
1. 5. 2   The new second messenger c-di-AMP 
1. 5. 2. 1  c-di-AMP synthesis and degradation 
c-di-AMP is a new second messenger that was first discovered in structural analysis of the DNA 
integrity scanning protein DisA of Thermotoga maritime revealing the diadenlyate cyclase (DAC) 
domain five years ago [195]. c-di-AMP is synthesized by condensation of two ATP molecules by 
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DAC domain proteins and degraded to pApA by a specific phosphodiesterase, commonly named 
GdpP (Figure 7). The DAC domain is found in proteins of 275 species, predominantly in the Gram-
positive phyla Firmicutes and Actinobacteria but also in Gram-negative genera Bacteroides, 
Cyanobacteria and Chlamydia among others, and even in certain Archaea species [196,197]. Besides 
DisA, there are two additional DAC domain proteins in B. subtilis, DacA (also called CdaA and YbbP) 
and DacB (also called CdaS and YojJ) (Figure 8). C-di-AMP is essential for bacteria and therefore a 
B. subtilis DisA/DacA/DacB triple mutant as well as a DisA/DacA double mutant are not viable [198]. 
Deletion of DacA and DisA is likely deleterious because DacB was detected to be only expressed 
during sporulation [198-200]. DacA is expressed in vegetative cells, contains besides the DAC domain 
a transmembrane domain, and it is homologous to the DAC proteins of L. lactis, Listeria 
monocytogenes, S. pyogenes and S. aureus, all of which possess only one protein with a DAC domain 
[125,201-203]. In contrast, Mycobacterium smegmatis possesses only one DAC domain protein 
homologues to DisA and a DacA protein is absent [197]. The activity of DacA in B. subtilis is 
specifically stimulated by the c-di-AMP synthase regulator CdaR (previously called YbbR), and 
Mehne et al. suggested that the same positive regulation may occur by YbbR of S. aureus [199]. 
Interesting to note is that the c-di-AMP degrading GpdP is inhibited by (p)ppGpp in B. subtilis 
connecting the signalling system of c-di-AMP with (p)ppGpp [204].  
 
 
Figure 7: c-di-AMP turn over in S. aureus. Adapted from [125]. 
 
1. 5. 2. 2  The predicted cellular role of c-di-AMP 
The cellular role and the regulatory mechanisms of c-di-AMP are not fully elucidated and only five c-
di-AMP receptors have been discovered so far. In S. aureus a screen for c-di-AMP receptors identified 
the potassium transporter-gating component KtrA; the predicted cation/proton antiporter CpaA; the 
two-component system sensor kinase KdpD; and the hypothetical PII-like signal transduction protein 
PstA, as c-di-AMP binding proteins (Figure 8, [205]). KtrA and CpaA share a common domain, 
RCK_C (regulator of conductance of K+), found in transporters, antiporters and channels, in all 
kingdoms of life. KtrA interacts with a membrane component responsible for the uptake of potassium 
named KtrB [205]. The c-di-AMP receptor KdpD phosphorylates the response regulator KdpE that is 
a possible c-di-AMP signal transduction pathway [205]. DisA contains in addition to the DAC domain 
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a DNA-binding domain and was suggested to sense DNA damage via the reduction of cellular c-di-
AMP levels in B. subtilis that possibly prevents entering sporulation (Figure 8, [195,206]). Targets or 
receptor proteins of c-di-AMP in B. subtilis were not identified so far. In Mycobacterium smegmatis a 
TetR-like transcription factor DarR was detected as c-di-AMP target protein and confirmed to 
negatively regulate three target genes and its own expression in a c-di-AMP dependent manner (Figure 
8, [207]). The target genes of c-di-AMP dependent regulation by DarR are the cold shock protein 
CspA, a medium fatty acyl-CoA ligase and a major facilitator family transporter (Figure 8, [207]).  
 
 
 Figure 8: Overview of c-di-AMP receptor and target proteins of S. aureus, B. subtilis and M. smegmatis. 
Environmental signals are indicated as lightning bolts and c-di-AMP is shown as yellow circle. Adapted from 
[197]. 
 
Independently of the recently discovered receptors, various studies of gdpP mutants in different 
bacterial species showed that c-di-AMP influences cell envelope homeostasis. Point mutations in gdpP 
and deletion of gdpP increase beta-lactam resistance of B. subtilis, L. monocytogenes, L. lactis and 
both MSSA and MRSA strains [125,198,202,203,208-211]. Deletion of gdpP in S. aureus increases 
the c-di-AMP level up to 15-fold and results in increased peptidoglycan cross-linking, autolysis, salt 
sensitivity, biofilm formation and a 13% reduced cell size [125,205]. Acquisition of point mutations in 
gdpP and deletion of gdpP were shown to rescue the absence of the essential cell wall component 
lipoteichoic acids in S. aureus, suggesting that elevated c-di-AMP levels could be a cell envelope 
stress response [125]. In L. lactis gdpP deletion or acquisition of point mutations in gdpP resulte in 
addition to decreased penicillin sensitivity in increased temperature tolerance and decreased salt 
tolerance [202]. Deletion of gdpP (also called pdeA) in L. monocytogens increases expression of acid 
stress response genes [203]. Studies in B. subtilis and L. monocytogenes revealed that the c-di-AMP 
level is tightly regulated and that both elevated and depleted levels of c-di-AMP are detrimental for the 
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growth of the bacteria [199,203]. With the currently limited knowledge on the function of the 
identified c-di-AMP receptors, it is not possible to explain all observed phenotypes and it is likely that 
there might be more receptors to be discovered. However, the current knowledge from analysis of 
altered c-di-AMP levels suggests a cell envelope or cell envelope stress related function of c-di-AMP. 
 
The genetic region of dacA of S. aureus and B. subtilis supports a connection of c-di-AMP to the cell 
envelope. Both S. aureus and B. subtilis form a three gene operon dacA-ybbR-glmM and dacA-cdaR-
glmM [109,199], respectively, including the phosphoglucosamine mutase glmM that catalyses the first 
step of the cell wall precursor UDP-N-acteyl glucosamine synthesis pathway [212]. The third gene of 
the operon encodes the above mentioned DacA regulator CdaR and its S. aureus homologue YbbR, 
respectively [109,199]. In B. subtilis the glucosamine-6-phosphate synthase gene glmS is located 
directly downstream of glmM and an additional large transcript dacA-ybbR-glmM-glmS is formed 
[199]. In contrast, glmS in S. aureus is separated from glmM by about 14 kb that contains the cell wall 
associated protein fmtB (also called mrp) as well as mannitol synthesis and export genes [109]. A 
larger transcript including fmtB but not glmS has been detected in S. aureus (dacA-ybbR-glmM-fmtB) 
[213]. 
 
Besides the effects on the bacteria, c-di-AMP is a host immune stimulator and was suggested as 
mucosal vaccine adjuvant [214]. L. monocytogenes secretes c-di-AMP via two multidrug efflux pumps 
belonging to the major facilitator superfamily, MdrT and MdrM [215,216]. Secretion of c-di-AMP 
triggers a type I interferon response that is suggested to be crucial for establishing L. monocytogenes 
infections [203,215,217]. A similar immune stimulation of c-di-AMP was detected for Chlamydia 
trachomatis, the first Gram-negative bacterium confirmed to produce c-di-AMP [210]. However, 
whether the induction of a type I interferon response is generally an advantage for the host or the 
bacteria is still debated [218]. 
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2 Aim of the study 
The aim of this project was to investigate factors that influence resistance or intrinsic tolerance of 
S. aureus to antibiotics. For Project I the goal was to determine induction kinetics of the VraSR-
dependent cell wall stress stimulon for various cell wall active antibiotics and to validate the role of 
the VraSR two-component system for intrinsic resistance to cell wall antibiotics. In Project II the role 
of LCP proteins in cell envelope biosynthesis and their connection to the cell wall stress stimulon and 
antibiotic resistance was aimed to be determined. Project III aimed to discover new factors that 
influence beta-lactam resistance and fitness of MRSA using a whole genome sequencing approach. 
The goal of Project IV was to analyse the effect of amoxicillin and minocycline administration on 
fitness and antibiotic resistance of the commensal S. aureus population in healthy volunteers. 
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Figure S1 
 
 
Figure S1 - CWSS expression in LCP mutant strains measured with pvrap-luc+. 
Luciferase activity, in relative light units (RLU), at different growth stages of LCP mutants from reporter 
construct pvrap-luc+. Left, single LCP mutants; middle, LCP double and triple mutants; right corresponding OD 
values of the cultures at each sampling point for all strains. Samples were taken at 1.5 h intervals for 7.5 h. 
Different RLU scales are used for different graphs in order to accommodate the ranges of RLU measured and 
highlight strain-dependent differences. Average values and standard deviations from three independent 
experiments are shown. 
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3.3.  Project III:  
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Table S1:  Complete l is t  of  d i f ferences in BB255, ME51 and RA120 compared to the 
NCTC8325 sequence inc luding SNPs and DIPs ident i f ied by Berscheid et a l.  2012 
[55] .  
Posi t ion1  
 
Ref 2  Seq3  Impact1  Locus 
(S AOUHSC_) 1  
Descr ipt ion 4  
5286  G A Gly85Ser  00166  DNA gyrase,  ATP hyd ro lyz i ng 
subuni t e  B  
22181  C A   In tergen ic  
00018/00019  
Non-cod ing  
47652  T  -   In tergen ic  
00044/00045  
Non-cod ing  
73564  G T  Asn472Lys  00069  Par t ia l  spa  gene fo r  immunglobu l i n  
G b ind ing pro te in  A  
142255  G T  Gly200Trp  00136  CHP,  n i t ra te  t ranspor t  ATP-b ind ing 
pro t e in  Nr tD,  puta t i ve  ABC 
t ranspor t er  
210632  T  A  Asp454Glu  00190  CHP,  membrane domain  o f  
membrane-anchored                    
g lyce rophosphory l  d i es ter  
phosphodies te rase  
218932  C T  Asp63Asn  00197  Puta t i ve  acy l -CoA dehydrogenase 
domain  pro te i n   
230630  T  G S i lent  00209  Puta t i ve  PTS sys tem mal tose-and 
g lucose -spec i f i c  E I ICB component  
252494  G A Gly323Asp  00230  Two-c omponent  sensor  h is t id ine 
k inase LytS  
329229  T  C Leu131Ser  00314  Poss ib le  t ransc r ip t i ona l  regu la t or  
MarR fam i ly ,  MATE fam i ly  mul t i -
ant im ic rob ia l  ext rus i on p ro te in  
433209  A  T   In tergen ic  
00434/00435  
Non-cod ing  
523591  G A Glu431Lys  00524  DNA-d i rec ted RNA po lymerase beta  
subun i t  
541723  T  G  In tergen ic  
00535/00536  
Non-cod ing  
541724  G C  In tergen ic  
00535/00536  
Non-cod ing  
590402  G – Frame sh i f t  00591  CHP 
649126  G T S i len t  00661  CHP,  put a t i ve  l ipase/es terase 
841103  G T  S i len t  00877  I ron -su lphu r  c lus ter  assembly  
accessory  p ro t e in  
841139  G T  S i len t  00877  I ron -su lphu r  c lus ter  assembly  
accessory  p ro t e in  
947898  C –  Frame sh i f t  00973  Puta t i ve  g l ycosy l  t rans fe rase 
980692  C T  Pro301Leu  01009  Phosphor i bosy lam ino im idazo le  
carboxy lase,  ATPase subuni t   
1013608  G A Va l50Met  01044  CHP,  put a t i ve  t ransc r ip t i ona l  
regu la t or  
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Posi t ion1  
 
Ref 2  Seq3  Impact1  Locus 
(S AOUHSC_) 1  
Descr ipt ion 4  
1042000  T  –  Frame sh i f t  01078  50S r i bosomal  pro te i n  L32,  rpmF  
1160513  G A A la106Thr  01209  16S rRNA p rocess ing pro te in  RimM 
1160531  A  G Lys112Glu  01209  16S rRNA p rocess ing pro te in  RimM 
1180886  G – Frame sh i f t  01232  30S r i bosomal  pro te i n  S2,  rpsB  
1283784  C –  Frame sh i f t  01342  Exonuc lease SbcC 
1562913  A  T  S top337Lys  01649  Pept idas e,  rhomboid  fam i ly  pro te in  
1632635  –  A  Frame sh i f t  01726  Puta t i ve  tRNA methy l t rans ferase 
MnmA 
1636251  T  –  Frame sh i f t  01732  BadM/Rr f 2  fam i ly  t ransc r ip t iona l  
regu la t or  
1653482  G A 
 
S i len t  01748  tRNA-guanine t ransg l ycosy lase  
1683491  T  C Lys40Glu  01786  Trans la t ion  i n i t ia t i on  fac to r  IF -3  
( In fC)  
1733515  G T  Thr73Asn  01827  Septa t ion  r i ng  fo rmat ion regu la t or  
EzrA  
1733572  A  G Phe54Ser  01827  Septa t ion  r i ng  fo rmat ion regu la t or  
EzrA  
1981053  A  G Phe92Ser  02107  Puta t i ve  UDP-N-acet y lmuramyl -
t r ipept ide synthetase  
2087725  A  T  Phe218I le  02254  Chaperon in  GroEL  
2166163  G C Thr124Arg  02337  UDP-N-acety l g luc osam ine 
1-ca rboxyv iny l t rans ferase MurA  
2166183  C A  S i len t  02337  UDP-N-acety l g luc osam ine 
1-ca rboxyv iny l t rans ferase MurA  
2221850  C A  Ser244Tyr  02401  Puta t i ve  t ransc r ip t i ona l  ant i -
te rm inator  
2243145  G –  R0005  rRNA-16S r ibosomal  RNA  
2243146  G –  R0005  rRNA-16S r ibosomal  RNA  
2244932  C –  Frame sh i f t  02417  Puta t i ve  ATP-b ind ing p ro te in ,  
Mrp/Nbp35 fam i ly  
2244933  T  –  Frame sh i f t  02417  Puta t i ve  ATP-b ind ing p ro te in ,  
Mrp/Nbp35 fam i ly  
2296654  G – Frame sh i f t  02474  CHP 
2318272  G A  In tergen ic  
002512/ 02515  
Non-cod ing  
2318274  G T  In tergen ic  
002512/ 02515  
Non-cod ing  
2318290  C A   In tergen ic  
002512/ 02515  
Non-cod ing  
2331612  C A  A la30Ser  02527  Pept idog l ycan pent ag l yc ine 
in terpept ide b ios ynthet ic  p ro te i n  
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Posi t ion1  
 
Ref 2  Seq3  Impact1  Locus 
(S AOUHSC_) 1  
Descr ipt ion 4  
FmhB (FemX)  
2349916  G T  In tergen ic  
02555/02556  
Non-cod ing  
2349964  G –  In tergen ic  
02555/02556  
Non-cod ing  
2349972  A  –   In tergen ic  
02555/02556  
Non-cod ing  
2349980  T  –   In tergen ic  
02555/02556  
Non-cod ing  
2349986  A  –   In tergen ic  
02555/02556  
Non-cod ing  
2349990  A  –   In tergen ic  
02555/02556  
Non-cod ing  
2349995  T  –   In tergen ic  
02555/02556  
Non-cod ing  
2350002  T  –   In tergen ic  
02555/02556  
Non-cod ing  
2350004  C –   In tergen ic  
02555/02556  
Non-cod ing  
2350008  A  –   In tergen ic  
02555/02556  
Non-cod ing  
2350012  N –   In tergen ic  
02555/02556  
Non-cod ing  
2350016  A  –   In tergen ic  
02555/02556  
Non-cod ing  
2350100  T  C  In tergen ic  
02555/02556  
Non-cod ing  
2383630  G T S i len t  02591  CHP,  put a t i ve  membrane p ro te i n  
2383660  G T  S i len t  02591  CHP,  put a t i ve  membrane p ro te i n  
2420619  –  T  Frame sh i f t  02632  Te icop lan in  res is tance-assoc ia ted 
membrane pro te in  TcaB  
2446161  C G Glu71Asn 02662  PTS sys tem, suc rose-spec i f i c  I IBC 
component  Sc rA  
2446162  C A  Gly70Val  02662  PTS sys tem, suc rose-spec i f i c  I IBC 
component  Sc rA  
2446164  C –  Frame sh i f t  02662  PTS sys tem, suc rose-spec i f i c  I IBC 
component  Sc rA  (02661 +  02662 =  1  
or f )  
2446246  C T  S i len t  02662  PTS sys tem, suc rose-spec i f i c  I IBC 
component  Sc rA  
2446393  C A   In tergen ic  
02662/02663  
Non-cod ing  
2446402  C –   In tergen ic  
02662/02663  
Non-cod ing  
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Posi t ion1  
 
Ref 2  Seq3  Impact1  Locus 
(S AOUHSC_) 1  
Descr ipt ion 4  
2446423  C A   In tergen ic  
02662/02663  
Non-cod ing  
2446630  C T  His26Tyr  02663  CHP 
2446641  T  A  S i len t  02663  CHP 
2466536  T  C Lys349Glu  02681  Ni t ra t e  reduc tase,  a lpha subuni t  
2556234  A  G  In tergen ic  
02781/02782  
Non-cod ing  
2592013  A  –  Frame sh i f t  02813  Hypothet ica l  membrane p ro te in  
(02813 +  02814 =  1  o r f )  
2596878  C T  Gly107Asp  02818  MFS fam i ly  major  fac i l i t a t o r  
t ranspor t er  
2678563  T  C S i len t  02911  CHP 
2684051  C T  A la90Thr  02919  3-methy l -2 -oxobutanoate  
hyd roxymethy l t rans fe rase  
2689048  G T Va l353Leu  02923  Am ino ac id  permease  
2782821  C –  Frame sh i f t  03008  Im idazo le  g lyc ero l  phosphate  
synthas e subuni t  H isF  
1Genome pos it ions and locus numbers are according to NCTC8325 sequence 
(GenBank access ion CP000253). 2Reference nuc leot ide in NCTC8325. 3Sequenced 
nuc leot ide in BB255, RA120 and ME51 determined in th is study. 4Descr ipt ion of  
putat ive gene products and funct ions were taken f rom NCTC8325 annotat ions and 
were improved f rom annotat ions of  other S. aureus stra ins . Abbreviat ion: CHP, 
conserved hypothet ica l prote in.  
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ABSTRACT 
Background The opportunistic pathogen Staphylococcus aureus remains a major cause for hospital- 
and community-acquired infections, but is often carried in the nares of the healthy population without 
causing harm. Because S. aureus easily develop resistance or acquire resistance determinants, the 
effects of minocycline and amoxicillin administration on colonizing S. aureus of healthy volunteers 
was monitored during a 12-month period as part of the FP7 EU-project ANTIRESDEV. Results The 
prevalence of S. aureus in the participating volunteers was 47.7 %. All isolates were typed, resistance 
profiles were determined and growth rates measured as an indication for fitness. The majority of the 
strains were amoxicillin resistant due to the presence of beta-lactamase. No methicillin-resistant 
S. aureus (MRSA) strains were isolated. Resistance and fitness levels of persisting strains varied over 
time independent of minocycline or amoxicillin application. No antibiotic resistance development or 
acquisition of resistance was observed. Volunteers were found to carry just one specific S. aureus 
strain, with few exceptions carrying several strain types. One Volunteer carried two different S. aureus 
strains before amoxicillin administration. After one week amoxicillin treatment, these strains had been 
replaced by a third strain, which colonized this volunteer during the following two months. All three 
strains carried a beta-lactamase and were resistant to amoxicillin. However, they differed in the beta-
lactamase induction in response to amoxicillin as determined by measuring hydrolysis of the beta-
lactamase substrate chromacef. The S. aureus strain isolated after amoxicillin administration produced 
higher beta-lactamase levels upon amoxicillin induction than the first two strains. Conclusions The 
data of this study suggest that the correct application of amoxicillin and minocycline had no 
measurable effect on the colonizing S. aureus isolates in healthy volunteers regarding antibiotic 
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resistance development or acquisition. Strain specific, varying beta-lactamase induction levels might 
have led to a replacement of strains in one volunteer upon treated with amoxicillin.  
 
KEYWORDS 
ANTIRESDEV, amoxicillin, minocycline, Staphylococcus aureus, resistance, beta-lactamase  
 
BACKGROUND 
The opportunistic pathogen S. aureus can colonize the healthy population persistently or transiently 
(reviewed in (39)). Carriage of S. aureus increases the risk of infections (reviewed in (17)), which can 
be difficult to treat due to the ability of S. aureus to acquire and develop resistances towards virtually 
all currently used antibiotics (38). Often, resistances inflict a fitness cost because the determinants 
interfere with important biological processes (1, 8, 15). However, bacteria found ways of reducing the 
biological costs of resistance, e.g. by tightly regulating the expression of resistance determinants, by 
reducing the copy number of the elements carrying them, or by combining them with other features 
adapting their metabolism. One of the best studied resistance determinant of S. aureus is the bla 
operon conferring resistance to beta-lactamase sensitive beta-lactams. In the current model, binding of 
beta-lactams to the sensor transducer BlaR1 leads to autocatalytic cleavage of BlaR1 (40). Thereby 
BlaR1 is proposed to be activated and to cleave the repressor BlaI (23), leading to the de-repression of 
the entire bla operon encoding BlaR1, BlaI and the beta-lactamase BlaZ (5). Induction is afterwards 
down-regulated due to the degradation of beta-lactams by BlaZ, eliminating the activating signal, and 
by shedding of the sensor domain of BlaR1 which reduces the number of responsive BlaR1 proteins 
and degradation of BlaI (24). 
In addition to the ability to acquire a vast range of resistance determinants, the success of S. aureus is 
based on a multitude of virulence factors including microbial surface components recognizing 
adhesive matrix molecules (MSCRAMMs), secreted expandable repertoire adhesive molecules 
(SERAMs), proteases, lipases, capsule proteins and toxins. These allow an efficient adhesion to host 
matrix proteins, evasion of the host innate immune response and invasion of the human body 
(reviewed in (6)). Different S. aureus strains harbor a selection and different combinations of 
representatives from these virulence factor classes (22, 25). The success of S. aureus to colonize the 
nares is also influence by host factors such as variations between humans in the extracellular matrix 
produced and in the expression of factors of the innate immune system (reviewed in (17)).  
To study the effect of antibiotic administration on the human microbiota, in the FP7 EU-project 
ANTIRESDEV (http://www.ucl.ac.uk/antiresdev) healthy volunteers were treated either with 
amoxicillin, minocycline, clindamycin, ciprofloxacin or placebo and samples from several body sites 
were collected during a 12-month period (2). Here we present data for S. aureus isolates from the 
amoxicillin and minocycline study. A subset of strains was further characterized regarding the 
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expression of beta-lactamase, autolytic behavior, adhesion to and survival in the presence of lung 
epithelial cells and biofilm formation. 
 
RESULTS AND DISCUSSION 
Characterization of S. aureus isolates 
Of the 44 volunteers participating in the minocycline (MIN) and amoxicillin (AMX) ANTIRESDEV 
study (2), twenty-one (47.7 %) were carrying S. aureus transiently or persistently (Table 1). S. aureus 
was isolated mainly from the nose (86 of 90 isolates, 95.56 %) and four isolates (0.04 %) were 
sampled from the skin of the trunk (Tables 2-4). ANTIRESDEV volunteers were recruited in the 
nearer area of London, UK (2). Compared to a recent survey reporting a 25.4 % S. aureus prevalence 
in the UK (7), the percentage of our study was rather high. In the study of den Heijer et al. over 3000 
patients with non-infectious disorders visiting family doctors both in rural and urban areas were 
screened for S. aureus (7), thus different recruitment strategies and volunteer numbers might explain 
the differences in prevalence found. To determine the relatedness of the S. aureus strains, all isolates 
were typed by pulsed-field gel electrophoresis (PFGE). One representative strain per PFGE pattern 
was further characterized by multi-locus sequence typing (MLST), as well as spa, agr and ccr typing 
(Tables 2-4). Volunteers generally carried one specific strain, with the exception of volunteers 21 
(V021), 24 (V024) and 30 (V030). In V021, two different strains were isolated before the 
administration of AMX, ARD147 (isolate N-021-2010-9-29/A1) and ARD148 (isolate N-021-2010-9-
29/A2). After administration of the antibiotic, these had disappeared and instead a third strain was 
isolated ARD152 (isolate N-021-2010-10-6/A1) (Table 4). V024 was transiently colonized by two 
different strains after one month (N-024-2010-8-18/A1) and after 12 months (N-024-2011-7-20/A1) of 
AMX administration (Table 4). Also V030 was only transiently colonized with S. aureus: two 
different strains were found in the original sample N-030-2010-11-24/A3 collected after one month of 
AMX administration, of which only one (N-030-2010-12-20/A1) was isolated after two months (Table 
4) .  
Some of the volunteers were colonized discontinuously with their S. aureus strain, which could be due 
to a recovery rate of S. aureus below 100 % by nasal swabbing, as observed by others (28). 
Alternatively, transiently colonized nares from these volunteers could have been re-colonized from an 
endogenous source, i.e. from other body sites that might have been persistently colonized by their 
specific S. aureus strain.  
 
A total of 26 S. aureus strains with different PFGE types were MLST typed resulting in 12 different 
sequence types (ST) in the volunteers colonized with S. aureus. The most frequently found sequence 
types were ST5 (7 or 26.9 %), ST30 (4 or 15.3 %), ST8, ST45 and ST54 (all 2 or 7.6 %). Similar 
results were found in other studies (28). Two new sequence alleles were identified and deposited in the 
MLST database. For spa types, t002 was most frequently detected with 4 isolates (15.3 %), followed 
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by t008, t012 and t015 with each 2 isolates (7.6 %); these types rank among the top 11 in the current 
Ridom database, collecting spa types from all over the world (http://spa.ridom.de/index.shtml). In the 
isolates analyzed, we found agr types 1-3, but no agr 4 type. Despite the fact that no MRSA strains 
were obtained, we identified in the isolates from two volunteers, V030 and V037, ccr genes of the 
types 2 and 1, respectively. The ccr recombinases are typically found on staphylococcal cassette 
chromosome (SCC) elements harboring mecA, the gene encoding the beta-lactam resistance 
determinant PBP2a (14). However, ccr genes can also be associated with non-mecA SCC elements 
harboring other resistance determinants and virulence factors (27).  
To identify antibiotic resistances arising or present in the S. aureus strains, antibiograms were 
determined for a broad range of antibiotics and minimal inhibitory concentrations (MICs) for 
amoxicillin, minocycline, clindamycin, ciprofloxacin and erythromycin were assessed. Minimal 
doubling times under standard laboratory conditions were measured as an indication for fitness 
(Tables 2-4). Both MICs and doubling times varied over the time monitored, suggesting that strains 
were adapting to shifting conditions in the human host. However, no resistance development or 
acquisition was observed. Standard deviations of doubling times were rather large and no significant 
differences could be found during the time monitored. In addition, the number of volunteers being 
colonized with S. aureus at least over four consecutive samplings was limited to four, making it 
difficult to produce enough data for testing a possible link between changes in MIC levels to changes 
in doubling times.  
 
Stress tolerance of isolates from volunteer V021 
The exceptional colonization of volunteer V021 with three different S. aureus strains (ARD147, 
ARD148 and ARD152) within a relatively short time called for a more in-depth characterization of 
these isolates. Moreover, strains ARD147 and ARD148 were sampled before the treatment of 
volunteer V021 with AMX and disappeared thereafter, whereas strain ARD152 appeared after one 
week of antibiotic administration. Thus, it seemed possible that ARD152 had competitively replaced 
the strains ARD147 and ARD148. The three strain types were therefore analyzed regarding their 
ability to grow on different media, as an indication of their flexibility and ability to adapt to stressful 
conditions they might encounter in the nares or on the skin: desiccation/re-hydration, osmotic stress 
due to high salt concentration, low pH and fatty acids like linoleic acid (3, 16, 36).  
Desiccation and re-hydration tolerance was tested by determining the reduction of viability of V021 
isolates after a desiccation period of 7 days (Figure 1). No difference in the extent of viability loss due 
to desiccation was found, suggesting that ARD147 and ARD148 type strains had not disappeared due 
to a reduced ability to survive dehydration in the human nose. 
In addition, different media imposing various stress types typically encountered on the human body as 
part of the human innate host defense were tested: Growth at low pH, high salt concentration (a stress 
S. aureus undergoes for example in axillae after sweating, a site from where re-colonization of the 
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nose can happen) and the presence of long chain unsaturated free fatty acids such as linoleic acid, a 
major component of nasal fluids. All the isolates from volunteer V021 grew similarly well under such 
conditions (Figure 2).  
The production of certain enzymes, such as proteases and lipases, might favor nutrient acquisition. In 
addition, expression of extracellular carbohydrates, such as capsule or polysaccharide intercellular 
adhesin (PIA) can protect S. aureus from harmful substances like antibiotics or antimicrobial peptides. 
In addition, PIA is involved in biofilm formation, where cells again are relatively shielded from 
harmful substances and can persist locally while continuously shedding cells for dissemination in the 
human body. Congo red plates, where carbohydrate-positive colonies appear dry/crystalline, Müller-
Hinton (MH) plates containing Tween 60, a substrate for lipases, and skim milk plates for detection of 
proteases were used to test the ability of the V021 isolates to grow on diverse media and for the 
production of extracellular carbohydrates, proteases and lipases (Figure 3). Isolates ARD147 and 
ARD148 appeared bright red on Congo red plates clearly different from isolates sampled after AMX 
administration (ARD152, 153, 275-277, 292-294) which were dark and dry suggesting they produce 
more extracellular carbohydrates. ARD147 and ARD148 seemed to produce more lipases though, as 
judged from the pronounced halos observed on MH-Tween 60 plates, caused by precipitation of 
degradation products from stearic acid, the main component of Tween 60. Pigment formation on skim 
milk plates was much higher in the isolates ARD147 and ARD148 compared to later sampled isolates 
(ARD152, 153, 275-277, 292-294), which appeared flat and almost transparent by eye but were able to 
grow as well as ARD147 and ARD148 (Figure 3D). Protease production was almost undetectable in 
strains ARD148 and ARD152, whereas strain ARD147 was a strong protease producer (Figure 3E). 
Since the isolates ARD152, 153, 275-277, 292-294 behaved similarly under the tested conditions so 
far and showed the same PFGE profiles, ARD152 was chosen as a representative strain for the 
subsequent experiments. 
Biofilm formation can be involved in infections of the nose, ear and throat, and was therefore assessed 
to determine whether persistent colonization of volunteer V021 by strain type ARD152 was due to 
higher biofilm formation. ARD152 produced slightly more biofilm than strains ARD147 and ARD148 
(Figure 4), but the difference was not significant and the impact for persistence might be negligible. 
 
Autolysis of V021 isolates 
Cell envelope stability protects bacteria from many harmful substances, including antibiotics, salt 
stress and human innate defense mechanisms that destabilize the cell membrane, such as antimicrobial 
peptides or fatty acids (16, 30). Therefore, we tested the stability of the isolates ARD147, ARD148 
and ARD152 by performing autolysis assays. Spontaneous autolysis was tested under low ionic 
conditions, where autolysins are activated due to a dissipation of cations and protons from the 
envelope. Peptidoglycan, proteins, lipids and wall teichoic acids can influence cation homeostasis of 
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the outer surroundings of the cell. Autolysis can be induced by adding the detergent Triton X-100 
(TX), which has been reported to remove lipoteichoic acids that protect form autolysins.  
In the absence of an inducer, autolysis rates of the strains ARD147 and ARD148 were very similar; 
autolysis of strain ARD152 was slightly increased (Figure 5A). Addition of 0.01 % TX reproducibly 
reduced autolysis rates of strain ARD147 and ARD148 in the beginning before reaching similar levels 
as strain ARD152, whose autolysis rate was further increased by the addition of TX (Figure 5B).  
 
Beta-lactamase expression of V021 strains 
To further characterize the V021 isolates, we determined the activity of the beta-lactamase enzyme 
BlaZ under induced and uninduced conditions by measuring the hydrolysis of the substrate chromacef. 
Strains ARD147 and ARD152 induced their BlaZ in response to AMX stress, whereas in strain 
ARD148 no Blaz activity was detected (Figure 6). Interestingly, strain ARD152 had higher BlaZ 
activity than ARD147 both under induced and uninduced conditions. 
Since we could not detect beta-lactamase activity in strain ARD148, we performed control PCRs to 
confirm the presence of the gene blaZ. All three strains contained blaZ genes, but could only be 
amplified with certain primer pairs, indicating that their nucleotide sequence varied (data not shown). 
To assess whether blaZ encoded a functional beta-lactamase, disc tests using penicillin G were 
performed. In agreement with amoxicillin MIC determinations (Table 4), all three V021 isolates were 
resistant towards penicillin G according to EUCAST guidelines (R < 26 mm) and produced sharp zone 
edges (data not shown), which indicate the presence of a functional beta-lactamase. However, the 
inhibition zone diameter of ARD148 was considerably larger than the ones from ARD147 and 
ARD152 (25 mm, 17 mm and 18 mm, respectively), suggesting that the induction, production, 
secretion or activity of the beta-lactamase in ARD148 was reduced compared to strains ARD147 and 
ARD152. 
 
Adhesion, internalization and survival in non-professional phagocytes 
For adhesion to host cells, an important step for colonization, S. aureus produces a large and variable 
arsenal of surface proteins which allow binding of the bacterium to the host matrix. Internalization into 
non-professional phagocytes, such as epithelial cells can follow, and depending on the survival 
abilities, S. aureus can also persist and hide in host cells.  
Strains ARD147, ARD148 and ARD152 were tested for adhesion, internalization and survival using 
the lung epithelial cell line A549 (10). Strains ARD147 and ARD148 adhered better to A549 cells 
than ARD152 represented by higher percentages of adhered cells after one hour incubation relative to 
the initial inoculum (Figure 7A). Surprisingly, ARD152 seemed to be more invasive than strains 
ARD147 and ARD148 after a three hour incubation period. For invasion percentages of invasive 
bacteria relative to the inoculum incubated in cell culture medium for three hours are given (Figure 
7B).  
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CONCLUSIONS 
Treatment of healthy volunteers with amoxicillin and minocycline did not alter resistance or fitness 
levels of the colonizing S. aureus strains. No methicillin resistant strains were found, but the majority 
of the strains were positive for beta-lactamase and resistant to amoxicillin. No acquisition or 
development of resistance neither towards the used antibiotics nor to other antibiotics was observed. 
These data suggest that resistance development and acquisition does not frequently occur during 
standard antibiotic treatment.   
The majority of the volunteers carried just one S. aureus strain during the time monitored. The isolates 
from volunteer V021 were characterized into more detail because of the possibility that the strain 
ARD152, which was isolated after the amoxicillin treatment, could have competitively replaced the 
two strains ARD147 and ARD148 initially present in the nares. However, in the majority of the 
experiments carried out to determine the fitness of the three strains under various conditions, no 
difference was found between the three strains or ARD152 was found to be the least fit. However, the 
three strains differed in induction of their beta-lactamase activity in response to amoxicillin 
determined by measuring hydrolysis of the beta-lactamase substrate chromacef. Strain ARD152 
produced higher beta-lactamase levels than strains ARD147 and ARD148 upon induction. Although 
caution has to be taken by drawing conclusions from the results produced under laboratory conditions, 
this could have been an advantage for ARD152 during amoxicillin treatment and could have 
contributed to the disappearance of ARD147 and ARD148, leading to the colonization of volunteer 
V021 with strain ARD152 during two months.  
 
METHODS 
Origin of S. aureus isolates. 
Detailed information about the ANTIRESDEV minocycline (MIN) and amoxicillin (AMX) study 
design has been described elsewhere (2). Briefly, healthy volunteers (aged 18-40) without hospital 
admission or antibiotic treatment during the preceding 3 months were recruited from the nearer 
London area in the UK. Volunteers received either MIN (100 mg once daily for 7 days) or AMX (250 
mg three times per day for 7 days) or placebo. Samples from skin, nose, saliva and faeces were taken 
before and 7-10 days, 1 month, 2 months, 4 months and 12 months after administration of antibiotics. 
 
Typing of isolates. 
S. aureus isolates received from study partner were typed by PFGE as described previously (31). 
MLST typing was performed according to Enright et al. (9), spa types were determined following 
instructions given in (11). Typing of agr was done according to Lina et al. (21). ccr types were 
determined based on previous reports (12, 13, 19). Primers used are listed in Table 5. 
 
Resistance profiles. 
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Minimal inhibitory concentrations for MIN, AMX, clindamycin, ciprofloxacin and erythromycin were 
determined using the agar dilution method according to EUCAST guidelines (http://www.eucast.org). 
Additionally, antibiotic susceptibility was analysed using disc diffusion assays. Bacterial suspensions 
were adjusted to McFarland turbidity standard 0.5. Suspensions were swabbed on Müller-Hinton agar, 
antibiotic discs (SirScan® discs i2a, Montpellier, France) were spotted and plates were incubated at 
37°C for 24 h.  
 
Growth and minimal doubling times. 
Growth curves were monitored in Luria-Bertani (LB) broth using a plate reader (Power Wave XS, 
BioTek, Winooski, VT, USA) and minimal doubling times were calculated. Optical density at 600 nm 
(OD600) was measured every 3 min after short shaking of the plate.  
 
Desiccation experiments. 
Based on previous reports (3, 18) desiccation tolerance was tested as follows: Bacteria were grown 
overnight in LB, adjusted to an OD600 of 1. Twenty µl were dispensed into microtiter dishes, and either 
immediately serially diluted up to 10-7 for spotting on LB agar plates or dried in a laminar flow hood. 
After 7 days, 100 µl LB was added to the wells, plates were incubated for 15 min at room temperature 
to allow rehydration and bacteria were resuspended by repeated pipetting. Suspensions were diluted 
and spotted on LB agar plates as described above and compared to the plates from day zero.  
 
Lipase detection. 
Bacteria were prepared as described for the desiccation experiment and spotted on Müller-Hinton agar 
plates containing 0.01 % CaCl2 and 1 % Tween 60 (35-50 % palmitic acid, 47-55 % stearic acid, 
Sigma, St. Louis, MO, USA). Plates were incubated at 37°C at least three days and up to one week 
based on recommendations (20).  
 
Growth under stress conditions. 
Bacteria were prepared as described above and spotted on LB agar plates adjusted to pH 7 or pH 5, 
containing 2 M NaCl or increasing amounts of linoleic acid. Plates were incubated at 37°C for 24-48 
hours. 
 
Biofilm formation. 
Instructions described by Seidl et al. (33) were applied as follows: Bacteria were grown overnight in 
BHI supplemented with 1 % glucose (BHIG). The OD was adjusted to 0.05 with BHIG and 1 ml was 
added to 12-well flat bottom Nunclon Delta-treated polystyrene plates (Thermo Scientific, Waltham, 
MA, USA) in triplicate. Plates were incubated for 18 hours at 37°C. The medium was aspired and the 
adhering bacteria were washed three times with PBS pH 7.4. Plates were dried and cells were stained 
with a 0.1 % safranin solution. After washing three times with dH2O, 200 µl of a 30 % acetic acid 
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solution were added to the wells to dissolve the adherent dye. The absorbance of the suspended dye 
was measured at 530 nm as an indication for biofilm formation. Medium without bacteria was used as 
a negative control. 
 
Autolysis.  
Experiments were performed basically as previously described (32). Briefly, cells were grown to 
exponential growth phase (OD600 0.5), washed with 0.85 % NaCl and resuspended in 0.01 M Na-
phosphate buffer pH 7. The OD600 was adjusted to 0.5. Cultures were split in half and 0.01 % Triton X-
100 (Fluka) or an equal volume of PBS pH 7 was added. Cultures were incubated at 37°C and the 
decrease of OD600 was measured. 
 
Beta-lactamase testing. 
Overnight cultures were diluted to an OD600 0.05 and grown to an OD600 0.5 at 37°C in a shaking 
incubator. One ml of culture was snap-frozen in liquid nitrogen (time point zero) and the culture was 
split in two halves. One half was induced with 0.5 MIC AMX, the other with an equal volume of 
dH2O. Cultures were grown for another two hours. Every 20 min OD600 was recorded and 1 ml 
samples were taken and snap-frozen. For measuring beta-lactamase activity, samples were thawed on 
ice. Three 200 µl aliquots were adjusted to 990 µl with LB and kept on ice until the addition of 10 µl 
of a 10 mM chromacef solution (Sopharmia Inc., St. Joseph, USA), which structurally resembles the 
standard beta-lactamase substrate nitrocefin. Samples where then incubated at 37°C for 30-60 min, 
centrifuged at 16’000 g for 1 min in a table top centrifuge and the supernatant was transferred to a 
cuvette for measuring the absorption of the chromacef degradation product at 442 nm and at 600 nm to 
determine the amount of any remaining cellular debris. One ml LB was treated like the samples and 
used as blank. Beta-lactamase activity is given as degraded chromacef in nmol OD600-1 min-1. 
 
Adhesion and internalisation experiments. 
Adhesion and internalization experiments were performed as described before (4). Briefly, overnight 
cultures of S. aureus strains were diluted to OD 0.2 in PBS and 300 µl of the cell suspensions, 
corresponding to approximately 105 cfu/ml, were added to 10 ml DMEM plus (DMEM with high 
glucose, pyruvate, L-glutamine (Invitrogen, Carlsbad, CA, USA); plus 10 % fetal bovine serum 
(Sigma)). A549 cells were grown to confluency in 12-well cell culture plates, 1 ml S. aureus 
suspensions in DMEM plus were added and plates incubated at 37°C and 5 % CO2 for 1 hour or 3 
hours. Afterwards, cell layers were resolved using 0.25 % trypsin/EDTA (Sigma) after 10 min 
treatment with 10 mg/l lysostaphin to for internalization experiments (lysostaphin protection assay 
(35)). cfu of the inoculum and of bacteria recovered from cell cultures were determinate by plating 
appropriate dilutions in 0.85 % NaCl on sheep blood agar. Four replicates per experiments and three 
independent experiments in total were performed. 
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AVAILABILITY OF SUPPORTING DATA 
New MLST alleles and STs, as well as new spa types were submitted to the corresponding database 
curators for subsequent addition to the databases.  
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Table 1. Colonization pattern of volunteers carrying S. aureus during the ANTIRESDEV 
study. 
 
A) Placebo group (14 volunteers). 
V # SA 0 1 week 1 month 2 months 4 months 1 year 
011 2       
028 6       
040 4       
 
B) Minocycline group (15 volunteers). 
V # SA 0 1 week 1 month 2 months 4 months 1 year 
003 1       
004 1       
019 1       
022 4       
034 1       
037 6       
042 4       
129 2       
 
C) Amoxicillin group (15 volunteers). 
V # SA 0 1 week 1 month 2 months 4 months 1 year 
006 8       
008 11       
015 9       
017 5       
021 10       
024 2       
027 7       
030 2       
035 1       
139 2       
 
V, volunteer; # SA, total number of S. aureus isolates; yellow, colonized with S. aureus; grey, 
volunteer dropped out of study. 
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Table 5. Oligonucleotides used in this study. 
 
Designation Sequence (5’-3’) Remarks  Reference 
α2 AACCTATATCATCAATCAGTACGT ccr1 typing, rev (12) 
α3 TAAAGGCATCAATGCACAAACACT ccr2 typing, rev (12) 
α4 AGCTCAAAAGCAAGCAATAGAAT ccr3 typing, rev (12) 
α4.2 GTATCAATGCACCAGAACTT ccr4 typing, fwd  (19)  
agr1-4Sa-1 ATGCACATGG TGCACATGC agr typing, fwd (21) 
agr1Sa-2 GTCACAAGTACTATAAGCTGCGAT agr1 typing, rev (21) 
agr2Sa-2 TATTACTAATTGAAAAGTGCCATAGC agr2 typing, rev (21) 
agr3Sa-2 GTAATGTAATAGCTTGTATAATAATACCCAG agr3 typing, rev (21) 
agr4Sa-2 CGATAATGCCGTAATACCCG agr4 typing, rev (21) 
arcC-Up TTGATTCACCAGCGCGTATTGTC arcC, fwd MLST typing (9) 
arcC-Dn AGGTATCTGCTTCAATCAGCG arcC, rev MLST typing (9) 
aroE-Up ATCGGAAATCCTATTTCACATTC aroE, fwd MLST typing (9) 
aroE-Dn GGTGTTGTATTAATAACGATATC aroE, rev MLST typing (9) 
β2 ATTGCCTTGATAATAGCCTTCT ccr1-3 typing, fwd   (12) 
β4.2 TTGCGACTCTCTTGGCGTTT ccr4 typing, rev  (19)  
blaZ-F CAGTTCACATGCCAAAGAG blaZ, PCR B, fwd (29) 
blaZ-R TACACTCTTGGCGGTTTC blaZ, PCR B, rev (29) 
blaZ-F1 GATAAGAGATTTGCCTATGC blaZ, PCR C, fwd (26) 
blaZ-R1 GCATATGTTATTGCTTGACC blaZ, PCR B, rev (26) 
γF CGTCTATTACAAGATGTTAAGGATAAT ccr5 typing, fwd (13) 
γR CCTTTATAGACTGGATTATTCAAAATAT ccr5 typing, rev (13) 
glpF-Up CTAGGAACTGCAATCTTAATCC glpF, fwd MLST typing (9) 
glpF-Dn TGGTAAAATCGCATGTCCAATTC glpF, rev MLST typing (9) 
gmk-Up ATCGTTTTATCGGGACCATC gmk, fwd MLST typing (9) 
gmk-Dn TCATTAACTACAACGTAATCGTA gmk, fwd MLST typing (9) 
gyr297 TTAGTGTGGGAAATTGTCGATAAT gyrB, fwd (34) 
gyr574 AGTCTTGTGACAATGCGTTTACA gyrB, rev (34) 
pta-Up GTTAAAATCGTATTACCTGAAGG pta, fwd MLST typing (9) 
pta-Dn GACCCTTTTGTTGAAAAGCTTAA pta, rev MLST typing (9) 
tpi-Up TCGTTCATTCTGAACGTCGTGAA tpi, fwd MLST typing (9) 
tpi-Dn TTTGCACCTTCTAACAATTGTAC tpi, rev MLST typing (9) 
yqiL-Up CAGCATACAGGACACCTATTGGC yqiL, fwd MLST typing (9) 
yqiL-Dn CGTTGAGGAATCGATACTGGAAC yqiL, rev MLST typing (9) 
    
             Fwd, forward; rev, reverse 
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Figure 1 
 
 
Figure 1. Desiccation resistance of volunteer 21 isolates. Isolates (ARD numbers) sampled before 
the administration of amoxicillin (s0) and after one week (s1), one month (s2), and two months (s3) of 
administration, were analyzed regarding their desiccation tolerance. Overnight cultures were dispensed 
into microtiter dishes and dried. After 7 days, the dried cultures were resuspended in LB, serially 
diluted as indicated in the figure, spotted on agar plates and compared to the initial inoculum. 
Representative data from two independent experiments are shown.  
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Figure 2 
 
 
Figure 2. Stress tolerance of volunteer 21 isolates. Isolates (ARD numbers) sampled before the 
administration of amoxicillin (s0) and after one week (s1), one month (s2), and two months (s3) of 
administration, were analyzed regarding their tolerance to high salt concentrations, low pH and the 
presence of linoleic acid. Overnight cultures were dispensed into microtiter dishes, diluted up to 10-7 
and spotted on LB agar adjusted to pH 7, pH 5, containing 32 mg/l linoleic acid (LA) or 2 M NaCl. 
Representative data from two independent experiments are shown.  
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Figure 3 
 
 
Figure 3. Extracellular factors produced by volunteer 21 isolates. Isolates (ARD numbers) 
sampled before the administration of amoxicillin (s0) and after one week (s1), one month (s2), and two 
months (s3) of administration, were analyzed regarding their production of extracellular 
carbohydrates, lipases and proteases. Overnight cultures were dispensed into microtiter dishes, diluted 
up to 10-7 and spotted on BHI-Congo red agar (A), MH-Tween 60 (B) or skim milk agar plates (C). 
Blow up of dilutions of strains ARD147, ARD148 and ARD152 on skim milk plates (D). For better 
visualization of proteases, OD600 1 suspensions were dispensed into holes in skim milk plates (E). 
Representative data from at least two independent experiments are shown. 
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Figure 4 
 
Figure 4. Biofilm produced by volunteer V021 isolates. Isolates (ARD numbers) sampled before the 
administration of AMX (ARD147 and ARD148) and after one week (ARD152) were tested for 
biofilm formation on polystyrene plates. Adhering bacteria were stained with a 0.1 % safranin solution 
and the color intensities were quantified by measure absorption at 530 nm (A530). Means and standard 
deviations from three independent experiments are shown.  
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Figure 5 
 
Figure 5. Spontaneous and induced autolysis of volunteer V021 isolates. Strains ARD 147 (red 
diamonds), ARD148 (green triangles) and ARD152 (black squares) were grown to an OD600 0.5, 
washed and resuspended in low salt buffer. Suspensions were split and spontaneous autolysis (A, 
empty symbols) or induced autolysis with 0.01 % Triton X-100 (B, filled symbols) is shown. The 
autolysis rate was monitored by measuring the OD over time and is given in % of the initial OD. 
Means and standard deviations from three independent experiments are shown.  
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Figure 6 
 
Figure 6. Beta-lactam hydrolysis by isolates ARD147, ARD148 and ARD152. Strains were grown 
to an OD 0.5 and induced with 0.5 MIC AMX (filled symbols) or grown without AMX (empty 
symbols). Samples were taken every 20 min during two hours and beta-lactamase activity was 
determined by measuring hydrolysis of the chromogenic cephalosporin chromacef (Sopharmia Inc., St. 
Joseph, USA). Representative data from three independent experiments are shown where mean values 
and standard deviations from three technical replicates were determined. 
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Figure 7  
 
 
Figure 7. Adhesion, internalization and survival of V021 isolates in A549 cell cultures. Overnight 
cultures of strains ARD147, ARD148 and ARD152 were diluted in cell culture medium and added to 
confluent layers of A549 cells. Bacteria were allowed to adhere to lung epithelial cells for one hour, 
after which the amount of adhering bacteria was expressed in % of the initial inoculum (A). Mean 
values and standard deviations from three independent experiments. Invasion of lung epithelial cells 
was determined by measuring intracellular bacteria after 3 hours of incubation with lung epithelial 
cells and is given as % of the inoculum after 3 hours incubation in cell culture media (B). 
Representative data from three independent experiments are shown where. 
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4 Outlook 
The factors analysed in this project are interesting candidates for the possible development of drug 
adjuvants that could decrease cell wall antibiotic resistance and thereby increase efficacy of existing 
antibiotics. This study provides new insights into the important VraSR stress response to cell wall 
active antibiotics, the role of LCP proteins and the relevance of c-di-AMP for fitness and resistance of 
MRSA. Standard administration of amoxicillin or minocycline was found to have no significant effect 
on fitness and resistance of commensal S. aureus strains in healthy volunteers. There are still many 
unanswered questions for possible follow-up experiments on all projects: 
Even though there have been several studies on the VraSR signal transduction, the mechanism or the 
molecule inducing the sensor VraS is still unknown. A general stress signal for cell envelope 
disturbance was suggested that would be an interesting starting point for further investigation. 
Interesting is also follow-up investigation of the third component VraT and its role in signal 
transduction. 
For the investigation of LCP proteins the next step would be an enzymatic confirmation of the WTA 
ligase function of these proteins in S. aureus. Whole genome sequencing of the LCP triple mutant and 
the corresponding wild type strain MSSA1112 could reveal possible compensatory mutations allowing 
its survival, which could give insights into the essentiality of the LCP protein family in S. aureus. 
The knowledge on c-di-AMP is currently very limited and research on c-di-AMP is especially 
interesting since c-di-AMP is essential for bacterial growth, lowered c-di-AMP levels reduce beta-
lactam resistance and c-di-AMP is universally present in bacteria but absent in humans, making it a 
promising drug target. The current knowledge on c-di-AMP targets and receptor proteins cannot 
explain all phenotypes connected to altered c-di-AMP levels, suggesting more targets could exist. C-
di-AMP targets could be identified by general approaches, like proteomics, transcriptomics, 
metabolomics as well as pull down experiments with biotinylated c-di-AMP. c-di-AMP influences 
virulence and secreted c-di-AMP from L. monocytogenes stimulates a type I interferon response. A 
follow-up project could analyse the contribution of c-di-AMP to virulence in S. aureus and investigate 
if c-di-AMP is secreted by S. aureus.  
The effect of amoxicillin and minocycline administration on the S. aureus population of healthy 
volunteers could be further validated using a larger number of S. aureus carriers and increasing 
frequency of sampling points to enhance the significance. Interesting would also be to compare the 
effect on volunteers from different countries that vary in their commensal S. aureus population.  
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ABSTRACT 
The LytR-CpsA-Psr (LCP) proteins are thought to transfer bactoprenol-linked biosynthetic 
intermediates of wall teichoic acid (WTA) to the peptidoglycan of Gram-positive bacteria. In Bacillus 
subtilis, mutants lacking all three LCP enzymes do not deposit WTA in the envelope, while 
Staphylococcus aureus ∆lcp mutants display impaired growth and reduced levels of envelope 
phosphate. We show here that the S. aureus ∆lcp mutant synthesized WTA yet released ribitol-
phosphate polymers into the extracellular medium. Further, ∆lcp mutant staphylococci no longer 
restricted the deposition of LysM-type murein hydrolases to cell division sites, which was associated 
with defects in cell shape and increased autolysis. Mutations in S. aureus WTA synthesis genes (tagB, 
tarF or tarJ2) inhibit growth, which is attributed to the depletion of bactoprenol, an essential 
component of peptidoglycan synthesis (lipid II). The growth defect of S. aureus tagB and tarFJ 
mutants was alleviated by inhibition of WTA synthesis with tunicamycin, whereas the growth defect 
of the ∆lcp mutant was not relieved by tunicamycin treatment nor by mutation of tagO, whose product 
catalyzes the first committed step of WTA synthesis. Further, sortase A-mediated anchoring of 
proteins to peptidoglycan, which also involves bactoprenol and lipid II, was not impaired in the ∆lcp 
mutant.  We propose a model whereby the S. aureus ∆lcp mutant, defective in tethering WTA to the 
cell wall, cleaves WTA synthesis intermediates, releasing ribitol-phosphate into the medium and 
recycling bactoprenol for peptidoglycan synthesis. 
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INTRODUCTION 
The peptidoglycan layer protects Gram-positive bacteria from osmotic lysis and serves as a barrier 
against membrane toxic compounds (1). Peptidoglycan also functions as a scaffold for the 
immobilization of capsular polysaccharides (2), wall teichoic acids (WTA) (3) and proteins (4). 
Surface proteins are anchored by sortase A, a membrane embedded transpeptidase that scans secreted 
polypeptides for the LPXTG motif of sorting signals (5). Sortase A cleaves the peptide bond between 
the threonine and the glycine of the LPXTG motif to form a thioester-linked intermediate between the 
carboxyl group of threonine at the C-terminal end of surface proteins and its active site cysteine 
residue (5, 6). The sortase A acyl intermediate is resolved by the nucleophilic attack of the free amino 
group of the pentaglycine crossbridge within lipid II (7, 8), the substrate for peptidoglycan 
biosynthesis (9). Surface protein linked to lipid II is incorporated into the cell wall envelope via the 
transpeptidation and transglycosylation reactions of peptidoglycan synthesis (10-12). In 
Staphylococcus aureus, lipid II is comprised of C55-PP-MurNAc-(D-Ala-D-iGln-(NH2-Gly5)-L-Lys-D-
Ala-D-Ala)-GlcNAc, i.e. a murein disaccharide-pentapeptide subunit linked to the membrane carrier 
bactoprenol (C55). In Gram-positive bacteria, bactoprenol/undecaprenyl is also used for the synthesis 
of extracellular polymers such as wall teichoic acid (WTA) (13), teichuronic acid (14) and cell wall 
polysaccharides (15).  
 
S. aureus WTA is a polymer of 30 to 50 ribitol-phosphate (Rbo-P) subunits connected via 1,5-
phosphodiester bonds (16). Rbo-Pn is tethered to peptidoglycan via the murein linkage unit, GlcNAc-
ManNAc-(Gro-P)2-3 (17). Synthesis of the murein linkage unit is initiated by TagO (also referred to as 
TarO), which links UDP-GlcNAc and undecaprenyl-phosphate to generate C55-PP-GlcNAc (14, 18, 
19). The other WTA subunits are added to the undecaprenyl-linked intermediate via the enzymes 
TagA (ManNAc)(17, 20), TagBDF (Gro-P) and TarILJ (Rbo-P) (21-23). The product of this pathway, 
C55-PP-GlcNAc-ManNAc-(Gro-P)2-3-(Rbo-P)30-50, is presumably flipped across the plasma membrane 
by the TagGH transporter (24). Attachment of the WTA polymer to the C6-hydroxyl of N-
acetylmuramic acid within peptidoglycan [MurNAc-P-GlcNAc-ManNAc-(Gro-P)2-3-(Rbo-P)30-50] 
occurs during cell wall assembly (25). The first two genes of the WTA pathway (tagO tagA) can be 
deleted without abolishing staphylococcal growth (20, 26, 27). In contrast, tagBDFGHtarIJL cannot 
be deleted unless staphylococci carry inactivating mutations in tagA or tagO (28). This synthetic 
viable phenotype is explained as the limited availability of bactoprenol and its undecaprenyl-
phosphate derivatives (C55-PP and C55-P) for peptidoglycan cell wall biosynthesis (28).  WTA 
synthesis is blocked by tunicamycin, an antibiotic from Streptomyces clavuligerus that inhibits TagO 
(29). 
 
Kawai et al. proposed that a family of genes encoding the LytR-CpsA-Psr (LCP) proteins catalyzes 
attachment of the murein linkage unit of WTA to the peptidoglycan of Bacillus subtilis (30). B. subtilis 
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encodes three lcp gene homologues, designated tagTUV, which are positioned within gene clusters for 
WTA biosynthetic enzymes (30).  Simultaneous deletion of all three genes (tagTUV) is not compatible 
with bacterial growth unless bacilli lack the tagO gene. Blocking the expression of tagTUV causes a 
concomitant decrease in the synthesis of WTA (30).  Further, X-ray crystallography identified 
polyprenyl-phosphate bound to recombinant B. subtilis TagT or its S. pneumoniae Cps2A homologue, 
both of which also exert in vitro phosphatase activity (30, 31).  On the basis of these observations, 
Kawai et al. proposed that LCP enzymes recognize WTA or capsular polysaccharide synthesis 
intermediates as substrates for the formation of phosphodiester linkages formed between the C6-
hydroxyl of MurNAc in peptidoglycan and GlcNAc-ManNAc murein linkage units (30). In agreement 
with this model, mutants (∆lcp) lacking all of the three LCP homologues of S. aureus – lcpA (mrsR), 
lcpB (SA0908), and lcpC (SA2103) – do not harbor phosphate residues in the cell wall envelope (32) 
and cannot properly place cell division septa (33). Previous work left unresolved whether S. aureus 
∆lcp mutants are defective in the synthesis and/or the cell wall anchoring of WTA and whether their 
associated cell division defect is due to the sequestration of lipid II within the WTA pathway (32, 33). 
The present study was performed to address these questions. 
 
MATERIALS AND METHODS 
Bacterial strains, bacterial growth and reagents.  
S. aureus strains were grown in tryptic soy broth (TSB) or on tryptic soy agar (TSA) supplemented 
with appropriate antibiotics. Erythromycin (Erm) and chloramphenicol (Cm) were used at a 
concentration of 10 µg/ml, and tunicamycin (Tun), unless otherwise specified, at 1 µg/ml. To examine 
the effect of tunicamycin on bacterial growth, overnight cultures grown in the absence of tunicamycin 
were diluted (1:100) into 100 µl fresh TSB with or without tunicamycin and growth at 37°C was 
monitored every 15 min for 12 hours in a Synergy HT plate reader (BioTek) by measuring the 
absorbance at 600 nm (A600).  To assess cell viability, overnight cultures of candidate strains were 
started by inoculating an isolated colony from a fresh plate into fresh medium. The next day, a sub-
culture was prepared by diluting an aliquot of the overnight culture in tubes containing fresh medium 
(1:100). The tubes were placed at 37°C with shaking. Sample aliquots were removed from cultures 
after 3.5 h or 16 h, A600 values were recorded and aliquots were serially diluted and plated on agar. 
Colony forming units (CFU) were enumerated following incubation of plates at 37°C overnight. 
Bacterial strains and plasmids utilized in this study are listed in Table 1. Mutations in the three LCP-
encoding genes msrR, sa0908 and sa2103 have been described earlier (32). For convenience, the 
genes are designated herein as lcpA, lcpB and lcpC, respectively. The nomenclature of single, double 
and triple mutants has been changed accordingly: ∆lcpA (msrR), ∆lcpB (sa0908), ∆lcpC (sa2103), 
∆lcpAB (msrR/sa0908), ∆lcpAC (msrR/sa2103), and ∆lcpBC (sa0908/sa2103) refer to each of the 
single and double mutants. The designation ∆lcp is used to refer to the triple mutant lacking all three 
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lcp genes (msrR/sa0908/sa2103). Deletion of tagO (∆tagO) was achieved by allelic replacement using 
plasmid pKOR1 (34, 35). Transposon mutagenesis was performed using two plasmids, pFA545 and 
pBursa (36). Transposon mutants were isolated on agar plates containing tunicamycin and candidate 
clones were re-screened for tunicamycin-dependent growth. To analyze the anchor structure of surface 
proteins, S. aureus strains were transformed with plasmid pHTT4 (10), which provides for the 
expression of the hybrid protein Seb-MH6-Cws, where Seb and Cws represent secreted staphylococcal 
enterotoxin B and the cell wall sorting signal of protein A, respectively, separated by the engineered 
methionine-six histidine (MH6) affinity tag for purification.  
 
Purification of Seb-MH6-Cws and analysis of C-terminal anchor peptides.  
S. aureus MSSA1112 strains (wild-type and ∆lcp mutant) harboring pHTT4 (10), were grown to A600 
0.8.  Cells were washed and suspended in 50 ml of 50 mM Tris-HCl buffer (pH 7.5), supplemented 
with 5 mM phenylmethanesulfonyl fluoride (PMSF) and broken in a Bead-Beater instrument (Biospec 
Products Inc.). Crude lysates were centrifuged at 33,000 ×g for 15 min and sedimented material was 
suspended in 100 ml of 100 mM KH2PO4 (pH 7.5), containing 1% Triton X-100 and 1 mM PMSF. 
Samples were incubated for 3 h at 4°C with stirring to extract membrane lipids. Cell wall material 
containing Seb-MH6-Cws was sedimented by centrifugation at 33,000 ×g for 15 min, washed three 
times with 100 ml of 100 mM sodium phosphate buffer (pH 6.0) and suspended in 30 ml of 100 mM 
Tris-HCl buffer (pH 7.5) supplemented with 1 mM PMSF. Seb-MH6-Cws was purified as described 
previously (10, 37). Briefly, the sample was incubated with 2 mg of lysostaphin for 16 h at 37°C and 
centrifuged at 33,000 ×g for 15 min. The supernatant containing Seb-MH6-Cws was applied to gravity 
flow columns packed with Ni-NTA beads. The column was washed with 30 column volumes of buffer 
A (100 mM Tris-HCl buffer (pH 7.5), 150 mM NaCl) containing 10 mM imidazole. Seb-MH6-Cws 
was eluted in buffer A with 0.5 M imidazole. Protein in the eluate was precipitated with 
methanol/chloroform, dried under vacuum and solubilized in 3 ml 70% formic acid prior to the 
addition of a cyanogen bromide crystal. Samples were incubated for 16 h at room temperature in the 
dark. Reaction products were washed twice with water, suspended in 1 ml of buffer B (10 mM Tris-
HCl, 100 mM NaH2PO4, 6 M guanidine hydrochloride, pH 8.0) and applied to a gravity flow column 
packed with Ni-NTA beads equilibrated in buffer B. The column was washed with 10-volumes each of 
buffer B, buffer C (8 M urea, 100 mM NaH2PO4, 10 mM Tris-HCl) at pH 8.0, and buffer C at pH 6.3. 
Anchor peptides including H6-Cws were eluted in buffer C containing 0.5 M imidazole at pH 8.0. For 
mass spectrometry analysis, peptides were desalted onto C-18 matrix cartridges (Waters) that were 
pre-washed with 10 ml of acetonitrile (CH3CN) containing 0.1% trifluoroacetic acid (TFA), and 10 ml 
of 0.1% TFA in water. Peptides were eluted in 3 ml 60% CH3CN, 0.1% TFA, dried under vacuum and 
suspended in 50 µl 30% CH3CN, 0.1% TFA. A 0.5 µl aliquot of this suspension was co-spotted with 
0.5 µl of matrix, α-cyano-4-hydroxycinnamic acid (10 mg/ml in 50% CH3CN, 0.1% TFA). Samples 
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were subjected to MALDI-TOF mass spectrometry using the Autoflex Speed Bruker MALDI 
instrument. Ions were detected in linear positive mode. 
 
Wall teichoic acid preparations.  
WTA was extracted from murein sacculi as described (38). Briefly, cells from a 30-ml culture of S. 
aureus grown in TSB at 37°C to A600 1.0 were washed with 30 ml of buffer D [50 mM 2-(N-
morpholino)ethanesulfonic acid (MES), pH 6.5], and suspended in 30 ml of buffer D containing 4% 
sodium dodecyl sulfate (SDS), followed by boiling for 1 h in a water bath and centrifugation for 10 
min at 23,000 ×g. The sediment was washed twice in 1 ml buffer D containing 4% SDS, once in buffer 
D containing 2% NaCl, and once in buffer D. Following each wash, murein sacculi were sedimented 
by centrifugation 23,000 ×g for 10 min, and, after the final wash, the peptidoglycan was suspended in 
1 ml of 20 mM Tris-HCl buffer at pH 8.0, containing 0.5% SDS, 20 µg proteinase K and incubated at 
50°C for 4 h. Protease digested murein sacculi were washed once in buffer D containing 2% NaCl, 
thrice in water and suspended in 1 ml of 0.1 M NaOH for a 16-h incubation at room temperature with 
rotation, to hydrolyze WTA. Following sedimentation of NaOH-extracted murein sacculi at 23,000 ×g 
for 10 min, the supernatant containing the released WTA was transferred to a new tube and neutralized 
with 50 µl of 0.1 M acetic acid and 100 mM Tris-HCl pH 8.5 for subsequent analysis by 
polyacrylamide gel electrophoresis (PAGE). WTA was also precipitated from 100 ml culture 
supernatants of S. aureus grown in TSB at 37°C to A600 0.5 by adding three volumes of 95% ethanol 
and incubating at 4°C for 30 min. Precipitated material was sedimented by centrifugation (16,000 ×g 
for 15 min), washed with 70% ethanol, air-dried and suspended in 5 ml of 100 mM Tris-HCl (pH 7.5), 
containing 5 mM CaCl2, 25 mM MgCl2, DNase (10 µg/ml) and RNase (50 µg/ml). Samples were 
incubated for 3 h at 37°C and subjected to methanol/chloroform extraction. TA in the aqueous layer 
was dried under vacuum, and solubilized in 1 ml of 20 mM Tris-HCl (pH 8.0). 
 
Quantifying the phosphate content of the staphylococcal envelope.  
Murein sacculi were prepared as described previously and stored in water (39). The phosphate content 
was determined by incubating 45 µl of murein sacculi sample (A600 1.0) with 5 µl of trichloroacetic 
acid at 80°C for 16 h. Inorganic phosphate released by this treatment was quantified with a 
colorimetric assay where a mix composed of 6 N H2SO4, water, 2.5% ammonium molybdate, 10% 
ascorbic acid (in the ratios 1:2:1:1) was added at 1:1 (v/v) to TCA-treated preparations and incubated 
at 37°C for 90 min. Product formation corresponding to free phosphate was measured in a 
spectrophotometer at 820 nm (A820) and phosphate concentration in the samples was calculated from 
NaH2PO4 standards (concentration 0-800 µM). 
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Gel electrophoresis and immunoblotting.  
WTA was separated on polyacrylamide gels using a Bio-Rad Protean II xi electrophoresis cell (20 cm 
× 16 cm × 1 mm) (40). Following separation of extracts by electrophoresis, gels were incubated twice 
in 1mg/ml alcian blue for 20 min, followed by two 30 min washes with deionized H2O and staining 
with the Silver Stain Plus Kit (Bio-Rad). For comparative analyses of proteins, aliquots of cultures 
used for WTA analysis were removed, treated with lysostaphin (4 µg) and incubated at 37°C for 10 
min. Proteins in these lysates were precipitated with 7% trichloroacetic acid, washed once with 
acetone, dried, solubilized in 100 µl of 0.5 M Tris-HCl pH 8.0 containing 4% SDS and heated at 90°C 
for 10 min. Proteins were separated on 12% SDS-PAGE and transferred to poly(vinylidene difluoride) 
membrane (Millipore) for immunoblot analysis with appropriate polyclonal antibodies. 
Immunoreactive signals were revealed by using a secondary antibody coupled to IRDye© 680 and 
visualized with a Li-Cor Biosciences Odyssey imager. 
 
Phenotypic characterization of mutants.  
The ability of S. aureus mutants to bind purified LysM-mCherry was assessed as described previously 
(34, 41). Briefly, cells of logarithmically growing cultures were sedimented by centrifugation, washed 
in phosphate-buffered saline (PBS), and incubated with purified LysM-mCherry for 10 min. mCherry 
was used as a control. Following incubation, cells were washed twice in PBS and fixed in 4% 
paraformaldehyde in PBS prior to analysis by flow cytometry and fluorescence microscopy. 
Incubation with propidium iodide (Invitrogen) was used to evaluate the membrane integrity of mutants 
as compared to wild-type. Briefly, overnight cultures were diluted 1:100 into TSB containing 0 or 1 
µg/ml tunicamycin and cultured at 37°C for 3.5 h. Following centrifugation of 1 ml culture, cells were 
washed twice with PBS, fixed for 20 min with 4% paraformaldehyde and then blocked for 1 h in PBS 
with 1% bovine serum albumin.  Cells were incubated for 15 min with 10 nM SYTO 9 (Invitrogen) 
and 2 µg/ml propidium iodide in PBS, washed twice and suspended in PBS for flow cytometry 
measurements. 
 
Flow cytometry and microscopy.  
Flow cytometric analyses were performed using the BD-LSR-II cytometer.  mCherry fluorescence was 
quantified using the allophycocyanin (APC) parameter and gating on single cells using forward and 
side scatter. Staphylococci were gated using forward and side scatter, and SYTO 9-positive cells 
captured under the FITC parameter were analyzed for propidium iodide staining in the PerCP-A 
parameter.  The parameters for negative propidium iodide staining were determined using an unstained 
control. For fluorescence microscopy, images were captured on a Leica TCS SP2 AOBS laser-
scanning confocal microscope with a 100× objective using identical settings and exposure times 
between samples.  For transmission electron microscopy, bacterial cells were washed twice with 50 
mM Tris-HCl (pH 7.5), 150 mM NaCl, bathed in fixative (2% glutaraldehyde, 4% PFA, 0.1 M sodium 
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cacodylate buffer) overnight at 4°C, and post-fixed with 1% OsO4 in 0.1 M sodium cacodylate buffer 
for 60 min.  Fixed samples were stained in 1% uranyl acetate in maleate buffer for 60 min, serially 
dehydrated with increasing concentrations of ethanol, embedded in spurr resin for 48 h at 60°C, thin 
sectioned (90 nm) using a Reichert-Jung Ultracut device and post-stained in uranyl acetate and lead 
citrate.  The samples were imaged on the FEI Tecnai F30 with a Gatan charge-coupled device (CCD) 
digital micrograph. 
 
RESULTS 
The S. aureus ∆lcp mutant releases wall teichoic acid into the extracellular medium.  
A S. aureus mutant with all three lcp genes deleted harbors very little phosphate in its cell wall 
envelope, suggesting that the mutant does not synthesize WTA (32). We wondered whether S. aureus 
lcp mutants may also be defective in the cell wall anchoring of WTA (30). To examine these 
possibilities, murein sacculi were isolated from wild-type S. aureus MSSA1112 and its isogenic 
mutants lacking one (∆lcpA, ∆lcpB and ∆lcpC), two (∆lcpAB, ∆lcpAC and ∆lcpBC) or all three lcp 
genes (∆lcp).  WTA was released from murein sacculi via alkaline hydrolysis; Rbo-P polymers of 
variable length were resolved by PAGE and visualized by staining with alcian blue/silver. As controls, 
the murein sacculi of wild-type S. aureus harbored WTA, whereas treatment of staphylococci with 
tunicamycin, an inhibitor of TagO, blocked the synthesis and incorporation of WTA in to the cell wall 
(Fig. 1A, lanes 1 and 2). The minimal inhibitory concentration of tunicamycin to block WTA synthesis 
in S. aureus MSSA1112 was 1 µg/ml (Fig. S1). WTA was detected in the murein sacculi of each 
single and double lcp mutant (Fig. 1A, lanes 3 to 8) but not in sacculi prepared from the ∆lcp strain 
(Fig. 1A, lane 9). This WTA synthesis defect of the ∆lcp mutant was restored by transformation with 
plasmids expressing any one of the three LCP homologues, lcpA, lcpB, or lcpC (Fig. 1B, lanes 11-13).  
We also determined the cell wall phosphate content of the wild-type versus mutant strains via 
colorimetric assay.  Here, peptidoglycan was extracted and purified from exponentially grown bacteria 
and inorganic phosphate liberated by incubation in 10% trichloroacetic acid. Staphylococci incubated 
with tunicamycin synthesized and incorporated very little phosphate into the cell wall envelope (Fig. 
1C).  As already noted by Dengler et al. (32), Rbo-P was not detected in cell wall extracts derived 
from the ∆lcp mutant. Furthermore, the single mutants ∆lcpA and ∆lcpB, but not ∆lcpC, contained 
reduced levels of phosphate compared to wild-type as did each of the double mutants (Fig. 1C). 
Nevertheless, loss of two lcp genes did not cause clear synergistic effects in reducing the phosphate 
content of staphylococcal cell walls (Fig. 1C).  
 
We next examined whether Rbo-P polymer can be detected in the culture medium of ∆lcp 
staphylococci. Following growth in the presence or absence of tunicamycin, carbohydrates and 
teichoid acid polymers in the supernatant of centrifuged cultures from wild-type MSSA1112 or its 
∆lcp variant were precipitated with ethanol.  Teichoic acids were sedimented by centrifugation and 
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contaminating nucleic acids digested with DNase and RNase. Samples were extracted with methanol 
and chloroform to remove proteins. Teichoic acids in the aqueous layer were concentrated by 
lyophilization, suspended in water, subjected to PAGE and revealed by alcian blue/silver staining.  As 
controls, murein sacculi of wild-type MSSA1112 harbored Rbo-P WTA, whose synthesis was blocked 
by tunicamycin treatment (Fig. 1D).  Of note, Rbo-P polymer was detected in the extracellular 
medium of cultures from the ∆lcp mutant, but not those of wild-type S. aureus (Fig. 1D). Tunicamycin 
treatment of ∆lcp cultures abolished the release of the Rbo-P polymer into the culture medium (Fig. 
1D).  To ascertain that Rbo-P polymer release did not result from cell lysis or aberrant peptidoglycan 
turnover, we asked whether the ∆lcp mutant also released cytoplasmic proteins or other cell wall 
polymers such as sortase-anchored proteins in the medium.  We show that the hybrid protein Seb-
MH6-Cws, with the cell wall sorting signal of protein A, is properly tethered to the murein sacculus of 
the ∆lcp mutant. Immunoblotting analyses revealed that the hybrid is not aberrantly released into the 
extracellular milieu of ∆lcp mutant cultures as compared to wild-type staphylococci (Fig. S2). The 
cytoplasmic protein L6 was not detected in extracts of spent culture media, ruling out bacterial lysis as 
a mechanism for surface protein release into the culture medium (Fig. S2).  Thus, we conclude that the 
∆lcp mutant fails to deposit WTA in the cell wall envelope, and instead releases Rbo-P into the 
extracellular medium. Taken together, these data suggest that LcpA, LcpB and LcpC display 
overlapping functions in depositing WTA in the cell wall envelope, presumably by forming a 
phosphodiester bond between the C-6 hydroxyl of MurNAc and the murein linkage unit tethered to 
Rbo-Pn. 
 
Cell division and envelope defects of ∆lcp and ∆lcp∆tagO mutant staphylococci.  
In B. subtilis, deletion of all three lcp genes is not compatible with bacterial growth unless the mutant 
cells also harbor a deletion of the tagO gene (30).  In contrast, the S. aureus ∆lcp mutant, that also 
lacks all three lcp genes, continues to grow (A600), albeit at a slower rate than wild-type (Fig. S3). To 
assess the viability of staphylococcal cells, culture aliquots were removed, serially diluted and plated 
after 3.5 h to enumerate viable colony forming units (CFU). We observed a 3-log reduction in plating 
efficiency for the ∆lcp mutant as compared to wild-type MSSA1112 (Fig. 2A). Introduction of the 
∆tagO allele into the ∆lcp mutant neither restored plating efficiency to wild-type levels, nor enhanced 
growth of the mutant at the earlier 3.5 h timepoint  (Fig. 2A), when the LCP enzymes are 
predominantly expressed (42). Further, when growth was measured via absorbance of liquid cultures 
(A600), the ∆lcp∆tagO mutant replicated at a rate similar to the ∆lcp mutant, but not at the rate of its 
wild-type parent (Fig. S3). To measure the number of non-viable staphylococci, culture aliquots of the 
three strains were stained with propidium iodide to identify lysed bacteria with membrane damage via 
flow cytometry (Fig. 2B). These experiments revealed that 30.2% of ∆lcp cells and 18.7% of 
∆lcp∆tagO cells were positive for propidium iodide, compared to only 1.68% of wild-type cells (Fig. 
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2B). Wild-type and mutant staphylococci were fixed, thin sectioned and viewed by transmission 
electron microscopy. As expected, wild-type strain MSSA1112 formed round cells, with a thick cell 
wall envelope and cross wall septa positioned at mid cell, perpendicular to previous cell division 
planes (Fig. 2C). Uranyl acetate staining revealed the uniform deposition of WTA as electron dense 
deposits in the envelope of wild-type staphylococci (Fig. 2C) (43).  In contrast, the ∆lcp and 
∆lcp∆tagO variants generated deformed cells with thin, irregular envelopes lacking the WTA staining 
of wild-type staphylococci (Fig. 2C). Of note, the ∆lcp and ∆lcp∆tagO variants generated cross wall 
septa parallel to the previous division planes, indicating that the physiological mechanisms for the 
selection of cell division planes had been abolished in the ∆lcp and ∆lcp∆tagO mutants (Fig. 2C). 
Interestingly, this phenotype is also observed for the isolated tagO and lcpA mutants, the latter of 
which still produces WTA (33, 43). These data suggest that both WTA synthesis and assembly are 
important for physiological cell division (43). In conclusion, the growth delay observed in the ∆lcp 
mutant is not a direct result of the continued synthesis of WTA and cannot be restored by preventing 
WTA synthesis.  
 
Effect of tunicamycin on the generation of non-viable daughter cells by ∆lcp mutant 
staphylococci. Dengler et al. reported that tunicamycin treatment could partially alleviate the growth 
defect of ∆lcp mutant staphylococci, a phenotype that was also observed in our experiments (Fig. 3A). 
We wondered whether tunicamycin treatment also suppressed the phenotype of the ∆lcp mutant of 
non-viable daughter cells. Bacterial cultures were grown without or with 1 µg/ml of tunicamycin for 
3.5 h. Culture aliquots were serially diluted and plated on TSA for colony formation (Fig. 3A). As 
expected, the plating efficiency of wild-type MSSA1112 was slightly reduced when the strain was 
grown in the presence of tunicamycin. In contrast, the addition of tunicamycin did not affect the 
plating efficiency of the ∆lcp strain (Fig. 3A), a phenotype that is in stark contrast to strains with 
mutational lesions in genes of the WTA biosynthetic pathway. For example, disruption of S. aureus 
tagB, tarF or tarJ2 via bursa aurealis transposon insertion was conditional for the presence of 
tunicamycin in agar media, whereas the plating efficiency of the ∆tagO mutant was not (Fig. S3). The 
plating efficiency of ∆lcp strain and its sensitivity to tunicamycin were almost restored to wild-type 
levels upon transformation with plasmids that provide for the expression of any one of the three lcp 
genes (Fig. 3A). Of note, the reduction in plating efficiency was not always correlated with bacterial 
growth measured for wild-type and ∆lcp cultures via increases in A600 (Fig. 3A). As before, this 
difference can be explained by the generation of non-viable daughter cells, revealed by the increase of 
propidium iodide positive cells in the ∆lcp culture. While incubation of cultures with tunicamycin led 
to further increases in propidium iodide-positive ∆lcp cells, tunicamyin treatment did not affect the 
membrane integrity of wild-type staphylococci (Fig. 3B). Transmission electron microscopy revealed 
that tunicamycin treatment did not affect the overall morphology and cell division septum formation in 
wild-type cells; as expected, the outer electron dense layer of WTA was abolished when staphylococci 
6 Appendix 
120 
 
were grown in the presence of the antibiotic (Fig. 3C). Further, tunicamycin treatment of ∆lcp 
staphylococci did not change the aberrant gross morphology and septation defect of the mutant cells 
(Fig. 3C). These data show that tunicamycin treatment, an inhibitor of WTA synthesis, neither 
suppresses the cell division defect of ∆lcp staphylococci nor its generation of non-viable daughter 
cells. 
 
The lcp genes are not required for surface protein anchoring to the staphylococcal cell wall. 
Previous work identified lipid II as the peptidoglycan substrate of the sortase A-catalyzed 
transpeptidation reaction of surface protein anchoring to the cell wall envelope (8). Consistent with 
this model, surface protein anchoring can be blocked by treating staphylococci with inhibitors of lipid 
II polymerization (vancomycin or moenomycin) or bactoprenol metabolism (nisin) (8).  LCP proteins 
have been proposed to transfer WTA precursors [C55-PP-GlcNAc-ManNAc-(Gro-P)2-3-(Rbo-P)30-50] 
onto the glycan strands of peptidoglycan (30). Since both reactions—surface protein- and WTA-
anchoring—require bactoprenol-linked intermediates, we wondered whether sortase A-mediated 
protein anchoring is altered in S. aureus strains lacking the three LCP phosphotransferases (∆lcp 
strain).  To test this possibility, the wild-type parent strain MSSA1112 and the ∆lcp mutant were 
transformed with plasmid pHTT4, which provides for the expression of Seb-MH6-Cws, an engineered 
surface protein consisting of the N-terminal signal peptide and staphylococcal enterotoxin B (Seb) 
fused to the C-terminal cell wall sorting signal of protein A (Fig. 4A). Peptidoglycan preparations 
from both MSSA1112 strains (WT/pHTT4 and ∆lcp/pHTT4) were treated with lysostaphin to 
solubilize anchored Seb-MH6-Cws for purification via metal-chelating affinity chromatography (Fig. 
4B). Purified proteins were subjected to cyanogen bromide (CNBr) cleavage at methionine residues. 
C-terminal anchor peptides with their N-terminal six-histidine (H6) tag were again purified by affinity 
chromatography and analyzed by MALDI-MS (Fig. 4CD). Ion signals labeled with m/z 1665 [1] and 
m/z 1722 [3] correspond to surface protein anchor peptides with two or three glycine residues [H2N-
H6AQALPETGG(G)], which are released from the cell wall via lysostaphin cleavage (Fig. 4CD, Table 
2). Ion signals with m/z 1693 [2] and m/z 1750 [4] represent formylated peptides of compounds 1 and 
3 (Table 2). Compounds with m/z 3826 [5], m/z 3854 [6], and m/z 3903 [7] represent formylated or 
carbamylated anchor peptides with two or three glycine residues, also liberated via lysostaphin 
cleavage from the cell wall [NH2-VDSKDVKIEVYLTTKKGTMH6AQALPETG(G)]; these peptides 
were generated via incomplete CNBr cleavage of Seb-MH6-CWS at methionyl residues (Table 2). 
Thus, Seb-MH6-CWS anchor peptides with similar structure and abundance were liberated via 
lysostaphin treatment from the cell wall envelope of wild-type and ∆lcp mutant staphylococci. These 
data indicate that the absence of LCP enzymes does not affect sortase A-mediated anchoring of 
surface proteins in S. aureus. 
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Deposition of LysM murein hydrolases in the envelope of ∆lcp mutant staphylococci.  
The decoration of the staphylococcal peptidoglycan with WTA restricts the binding of secreted murein 
hydrolases to the cell wall and limits the autolytic activity of these enzymes to the cross wall 
compartment of dividing staphylococci (44). For example, the deposition of the LytN and Sle1 murein 
hydrolases is restricted to the cross wall (34, 41). Each of these enzymes harbors LysM domains at 
their N-termini (34). LysM domains are both necessary and sufficient for the targeting of Sle1 to the 
cross wall (34). Inhibition of WTA synthesis, for example treatment of staphylococci with 
tunicamycin or deletion of tagO, abolishes the specificity of LysM-domain targeting to the bacterial 
envelope (34). In a confocal fluorescence microscopy experiment, an abundance of LysMLytN-mCherry 
and LysMSle1-mCherry was found deposited uniformly throughout the envelope of tagO mutant, but 
not wild-type staphylococci (34)(Fig. 5A). As a control, mCherry alone did not bind to the 
staphylococcal envelope. We wondered whether the ∆lcp mutant, which fails to deposit WTA in the 
staphylococcal envelope, is also defective for the targeting of LysM-type murein hydrolases. Similar 
strong binding activities of LysMLytN-mCherry and LysMSle1-mCherry were observed for the ∆lcp 
mutant strain, but not for its MSSA1112 parent (Fig. 5A). 
 
The deposition of mCherry, LysMLytN-mCherry and LysMSle1-mCherry on the staphylococcal surface 
was quantified by measuring bacterial fluorescence in a flow cytometry experiment (Fig. 5B).  A 10- 
and 100-fold increase in LysMLytN-mCherry and LysMSle1-mCherry fluorescence, respectively, was 
measured with ∆lcp mutant staphylococci relative to the wild-type strain MSSA1112.  These 
differences were comparable to those observed between wild-type and ∆tagO mutant staphylococci 
(Fig. 5B).  As a control, mCherry did not bind to the envelope of wild-type, ∆tagO, or ∆lcp mutant 
staphylococci (Fig. 5AB). These data suggest that the WTA deposition defect of the ∆lcp mutant 
causes the unrestricted deposition of murein hydrolases in the bacterial envelope, a phenotype that 
likely contributes to the decreased viability of ∆lcp daughter cells generated during cell division. 
 
DISCUSSION 
Recent reports implicated a family of genes encoding the LCP proteins in WTA synthesis and in the 
attachment of secondary cell wall polymers to bacterial peptidoglycan (30, 31). LCP-encoding genes 
are present in virtually all Gram-positive bacteria, often numerous homologues within a single genome 
(45).  The LCP proteins share a similar predicted secondary structure, consisting of a short N-terminal 
cytoplasmic tail, a single transmembrane domain, and an extracellular C-terminal region 
encompassing a mixed α-helical/β-sheet “LCP” domain (30, 45).  While the biochemical activity of 
these proteins is still not known, variants carrying defective alleles of lcp genes display pleiotropic 
phenotypes.  For example, in both S. aureus and S. pneumoniae, loss of one or more of these genes 
resulted in aberrant septum formation (33, 46, 47), increased susceptibility to β-lactam antibiotics (33, 
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46), autolysis (33), aberrant biofilm formation (46), induction of cell wall envelope stress responses 
(32) and reduced cell wall phosphate (32).  B. subtilis contains three homologues of the LCP genes, 
tagTUV, which cluster with genes of the WTA synthesis pathway (30).  Deletion of all three genes is 
not compatible with growth of the mutant bacilli (30). Similar to late-stage WTA mutants, this 
phenotype can be rescued through the additional deletion of tagO (28); furthermore, tagTUV mutants 
cannot assemble WTA in the bacterial cell wall (30).  In S. pneumoniae, mutants with deletions of one 
or two of the LCP homologues (Cps2A, LytR and Psr) synthesize reduced amounts of capsular 
polysaccharide and release some of this material into the extracellular medium (31, 48, 49).  The 
crystal structures of recombinant B. subtilis TagT and S. pneumoniae Cps2A revealed the presence of 
a polyprenyl phosphate lipid bound to the purified protein (30, 31). These findings have led to the 
hypothesis that LCP enzymes transfer secondary cell wall polymers from their undecaprenyl-
phosphate precursors and link them to the bacterial peptidoglycan (30).  Specifically, LCP enzymes 
are proposed to tether the murein linkage unit of WTA or other secondary cell wall polysaccharides to 
the C6-hydroxyl of MurNAc in the peptidoglycan of Gram-positive bacteria (30). 
 
Although several layers of evidence support the hypothesis of Kawai and colleagues, there are also 
arguments against it. For example, S. pneumoniae is not known to express functional tagO tagA 
homologues or synthesize murein linkage units (C55-PP-GlcNAc-ManNAc); pneumococci are thought 
to anchor their teichoic acid polymers and capsular polysaccharides to the C6-hydroxyl of MurNAc 
via phosphodiester bonds with other carbohydrate structures (50). Further, if B. subtilis TagTUV or S. 
aureus LcpABC were to tether the murein linkage units of WTA to the cell wall, one would expect 
that the corresponding mutant strains either harbor WTA precursors [C55-PP-GlcNAc-ManNAc-Gro2-
3-(Rbo-Pn)] in the envelope or release unanchored products into the extracellular medium.   Although 
this was tested, the B. subtilis tagTUV mutant did not release WTA into the medium and did also not 
deposit WTA in the envelope (30). 
We are interested in sortase-mediated anchoring of surface proteins to the cell wall envelope (5), a 
biosynthetic pathway that also utilizes an undecaprenyl precursor, lipid II, to immobilize polypeptides 
in the bacterial envelope (7, 8, 51). We presumed that the S. aureus ∆lcp mutant may accumulate 
undecaprenyl-linked intermediates of the WTA pathway, thereby causing a block in surface protein 
anchoring. This, however, was not observed; instead, the S. aureus ∆lcp mutant synthesized WTA and 
released the Rbo-P polymers into the extracellular medium.  We surmise that the observed release of 
WTA may be catalyzed by undecaprenyl pyrophosphate phosphatases (UppPs), which are otherwise 
involved in the recycling of translocated lipid II (52). If so, this could explain why undecaprenyl 
recycling occurs in the ∆lcp variant but not in tagB, tarF or tarJ2 mutants, which require mutations in 
tagO/tagA or inhibition of WTA synthesis with tunicamycin for growth. We entertain a model 
whereby the S. aureus ∆lcp mutant translocates its WTA precursors via TagGH for subsequent 
hydrolysis via UppPs, thereby enabling the return of bactoprenol into the cytoplasm. This model could 
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also explain why other WTA biosynthetic intermediates, those accumulating in tagB, tarF or tarJ2 
mutants (without substrate properties for TagGH), either deplete staphylococci of the lipid carrier or 
accumulate toxic intermediates. It seems plausible that UppPs do not have access to cytoplasmic 
intermediates of the WTA pathway and therefore cannot relieve the growth inhibitory attributes of 
tagB, tarF or tarJ2 mutations. Our model offers insights for the development of new drugs that target 
key steps of WTA synthesis on the bacterial surface. At least for S. aureus, the causative agent of 
human infections with antibiotic resistant strains (53), small molecule inhibitors of LCPs would not be 
expected to cause bactericidal activity, whereas the combined inhibition of LCPs and UppPs may be 
associated with antibiotic activity. In contrast, the B. subtilis tagTUV mutant appears to sequester 
WTA synthesis intermediates, as these mutations inhibit the growth of the mutant unless WTA 
synthesis is blocked via tagO mutation (30). Thus, B. subtilis may lack the relevant UppP activity and 
cannot recycle WTA synthesis intermediates. A combined literature and Genbank search suggests that 
S. aureus encodes three genes with undecaprenyl pyrophosphate phosphatase activity. The canonical 
bacA/uppP gene has been described and is dispensable for growth (54). S. aureus also encodes two 
predicted phosphatases with a PAP2-domain reminiscent of ybjG and pgpB, two genes that have been 
shown to encode redundant UppP activities E. coli (52). A similar search performed for B. subtilis 
suggest that this organism encodes only two undecaprenyl pyrophosphate phosphatases, bacA 
(formerly yubB) and bcrC (formerly ywoA) (55).   
 
In sum, data reported here support the model of Kawai and colleagues whereby LCP enzymes catalyze 
the transfer of WTA synthesis intermediates to the cell wall peptidoglycan (30). The observed 
pleiotrophic phenotypes of the ∆lcp mutant are likely due to its WTA synthesis and WTA cell wall 
deposition defects. Without WTA, staphylococci display aberrant cell size, septum formation, 
autolysis, susceptibility to antibiotics and defects in biofilm formation (32, 33, 45, 46). The molecular 
basis of the observed phenotypes are likely due to defects in the positioning and functional 
coordination of the peptidoglycan biosynthesis and cell wall separation machines, which involve a 
wide spectrum of different enzymes. 
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Table 1. Strains and plasmids used in this study. 
Strain 
designation 
Genotype Description Source 
RN4220 Wild-type S. aureus laboratory strain, a restriction-deficient 
derivative of NCTC 8325-4 
(56) 
ΔtagO RN4220 tagO RN4220 lacking tagO (57) 
tagB::erm RN4220 tagB RN4220 with bursa aurealis insertion in tagB This work 
tarF::erm RN4220 tarF RN4220 with bursa aurealis insertion in tarF This work 
tarJ2::erm RN4220 tarJ2 RN4220 with bursa aurealis insertion in tarJ2 This work 
MSSA1112 Wild-type  Methicillin sensitive S. aureus, clinical isolate (58) 
ΔlcpA MSSA1112 
lcpA::erm 
MSSA1112 with ermB replacing lcpA (msrR) (46) 
ΔlcpB MSSA1112 lcpB MSSA1112 lacking lcpB (sa0908) (33) 
ΔlcpC MSSA1112 lcpC MSSA1112 lacking lcpC (sa2103) (33) 
ΔlcpAB MSSA1112 
lcpA/lcpB 
MSSA1112 lacking lcpA and lcpB (33) 
ΔlcpAC MSSA1112 
lcpA/lcpC 
MSSA1112 lacking lcpA and lcpC (33) 
ΔlcpBC MSSA1112 
lcpB/lcpC 
MSSA1112 lacking lcpB and lcpC (33) 
Δlcp MSSA1112 lcp MSSA1112 lacking all three lcp genes (33) 
ΔlcpΔtagO MSSA1112 
lcp/tagO 
MSSA1112 lacking all three lcp genes and tagO This work 
Plasmid 
designation 
Insert Description  
p∆tagO DNA segments 
flanking tagO 
pKOR1 carrying 1 kbp DNA segment upstream 
and downstream of tagO used for allelic 
replacement 
This work 
pHTT4 SEB-MH6-CWS pOS1 vector encoding staphylococcal enterotoxin 
B with the cell wall sorting motif of protein A 
(10) 
pBursa Modified 
mariner 
transposon  
Plasmid carrying the mariner based transposon 
with erythromycin resistance (thermosensitive 
replicon) 
(36) 
pFA545 Mariner 
transposase 
Plasmid carrying the transposase 
(thermosensitive replicon) 
(36) 
plcpA lcpA (msrR) Plasmid pGC2 (pT194-based) encoding lcpA for 
complementation studies 
(33) 
plcpB lcpB (sa0908) Plasmid pGC2 (pT194-based) encoding lcpB for 
complementation studies 
(33) 
plcpC lcpC (sa2103) Plasmid pGC2 (pT194-based) encoding lcpC for 
complementation studies 
(33) 
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Table 2. Sortase A-catalyzed surface protein anchoring to the cell wall is not altered in the 
∆lcp mutant.  
Ion 
 
WT/pHTT4 
Obs. m/z 
∆lcp/pHTT4 
Obs. m/z 
Calc. m/z Proposed Structure 
1 1665.941 1665.811 1665.729 NH2-H6AQALPET-Gly2-CO2H 
2 1693.893 1693.830 1693.739 HCO-NH-H6AQALPET-Gly2-CO2H 
3 1722.888 1722.827 1722.781 NH2-H6AQALPET-Gly3-CO2H 
4 1750.956 1750.867 1750.791 HCO-NH-H6AQALPET-Gly3-CO2H 
5 3826.572 3826.436 3826.215 NH2-VDSKDVKIEVYLTTKKGTMH6AQALPET-Gly2-
CO2H, Na
+
 
6 3854.116 3854.111 3854.225 HCO-NH-VDSKDVKIEVYLTTKKGTMH6AQALPET-Gly2-
CO2H, Na
+
 
7 3901.934 3902.469 3903.301 H2NCO-NH-VDSKDVKIEVYLTTKKGTMH6AQALPET-
Gly3-CO2H 
Cyanogen bromide cleavage products of cell wall anchored Seb-MH6-Cws liberated by 
lysostaphin treatment and purified by Ni-NTA chromatography (see Fig. 4) were analyzed by 
MALDI-TOF MS in linear positive mode.  The program CS ChemDraw was used for m/z 
calculations.  
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Figure 1 
 
 
 
FIG. 1. ∆lcp mutant cells lack cell-associated wall teichoic acid. (A and B) Alcian blue- and silver-
stained acrylamide gels of cell wall-associated WTA.  (A) WTA was extracted from S. aureus 
MSSA1112 wild-type (WT) grown without (lane 1) or with (lane 2) tunicamycin and from single 
(∆lcpA, ∆lcpB, ∆lcpC), double (∆lcpAB, ∆lcpAC, ∆lcpBC) and triple (∆lcp) mutant strains (lanes 3-9). 
(B) WTA was extracted from the triple (∆lcp) mutant strain carrying an empty vector (panel B, lane 
10) or complementing plasmids plcpA, plcpB, or plcpC (panel B, lanes 11-13).  As a control for the 
number of staphylococci, cell extracts were immunoblotted with antibodies specific for sortase A. (C) 
Quantification of phosphate levels in purified peptidoglycan from strains described in A. Average 
phosphate levels were derived from three independent experiments and the standard error of the means 
calculated.  Statistical significance between the WT and each group was determined using one-way 
analysis of variance (ANOVA) with Bonferroni’s multiple comparison test: symbols denote * p<0.05, 
** p<0.01, and *** p<0.001. (D) Identification of teichoic acid in the supernatant of ∆lcp cultures. 
WT and ∆lcp strains were grown in the absence (-) or presence (+) of tunicamycin, and teichoic acids 
in cell pellets (left panel) or culture supernatants (right panel) were resolved by PAGE and visualized 
by staining with alcian blue and silver.  
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Figure 2 
 
 
 
 
FIG. 2. Deletion of tagO does not improve growth of the ∆lcp mutant. (A) Staphylococcal viability 
was examined by plating serial dilutions (0- to 6-fold) of culture aliquots of WT, ∆lcp, and ∆lcp∆tagO 
mutants that had been grown for 3.5 and 16 h, respectively. Images of the agar plates are shown along 
with absorbance values of cultures at 600 nm (A600) at the time of plating. (B) Membrane integrity of 
staphylococci was assessed with propidium iodide staining. Culture aliquots of WT, ∆lcp, and 
∆lcp∆tagO mutants that had been grown for 3.5 h were fixed with paraformaldehyde and stained with 
SYTO 9 (total cells) and propidium iodide.  SYTO 9-positive cells were analyzed for propidium 
iodide staining using flow cytometry.  Combined data from two independent experiments with 
triplicate analyses of 20,000 cells/sample are presented.  Statistical significance was determined using 
the Student’s t test (* denotes p < 0.05). (C) Transmission electron micrographs of WT, ∆lcp, and 
∆lcp∆tagO bacteria. Cells were cultured for 3.5 h as in panel A. Scale bars represent 200 nm. 
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Figure 3 
 
 
 
 
FIG. 3. Inhibition of TagO with tunicamycin does not suppress the growth defects of the ∆lcp 
mutant. (A) Bacterial growth was examined by plating serial dilutions of cultures grown for 3.5 h 
without or with tunicamycin (0 or 1 µg/ml). Culture aliquots of WT and the ∆lcp mutant without or 
with plcpA, plcpB, or plcpC were spotted on agar plates. A600 values were recorded at the time of 
plating are reported under the images of agar plates. (B) Membrane integrity of staphylococci assessed 
with propidium iodide staining. Culture aliquots of WT and ∆lcp mutant grown for 3.5 h without or 
with tunicamycin (0 or 1 µg/ml) were fixed and stained as described in Fig. 2B. The data were 
analyzed as described in Fig. 3B (* p < 0.05). C. Transmission electron micrographs of WT and ∆lcp 
mutant cells from cultures grown for 3.5 h without or with tunicamycin (0 or 1 µg/ml). Scale bars 
represent 200 nm. 
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Figure 4 
 
 
 
 
FIG. 4.  Sortase A-anchoring of proteins to the cell wall is not affected in the ∆lcp mutant. (A) 
Diagram of recombinant SEB-MH6-CWS encoded by the pHTT4 plasmid. Cleavage sites of signal 
peptidase, sortase A and  cyanogen bromide (CnNBr) are indicated. (B) Coomassie-Brilliant Blue-
stained SDS-PAGE of SEB-MH6-CWS released with lysostaphin from the cell wall of either wild-type 
(left) and ∆lcp mutant (right) staphylococci. Solubilized cell wall preparations (lanes 1) were 
subjected to affinity chromatography on Ni-NTA beads. Material not retained on the column is shown 
in lanes 2. The beads were washed (lanes 3) and SEB-MH6-CWS eluted with buffer containing 0.5 M 
imidazole (lanes 4). Molecular weight markers (MW in kDa) are indicated on the right side of the gel. 
(C and D) Mass spectrometry of CNBr cleaved SEB-MH6-CWS purified from wild-type (C) and ∆lcp 
mutant (D). Proteins eluted in lanes 4 panel B were digested with CNBr and fragments were purified 
once more over Ni-NTA, eluted, desalted and subjected to MALDI-TOF MS. The analysis of the ion 
signals labeled 1-7 and structural predictions are listed in Table 2. 
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Figure 5 
 
 
 
 
FIG. 5.  The LysM domains of LytN and Sle1 bind uniformly to the envelope of the ∆lcp mutant. 
Purified mCherry, LysMLytN-mCherry, or LysMSle1-mCherry were incubated with wild-type parent 
(strains RN4220 and MSSA1112), ∆tagO or ∆lcp staphylococci. Binding of hybrid mCherry to the 
bacterial envelope was analyzed by fluorescence microscopy (A) and flow cytometry (B).  The left 
panels in (A) display the DIC image of staphylococcal cells analyzed by fluorescence microscopy 
(middle panels).  The right panels display merged images derived from both data sets.  
 
